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ABSTRACT 
 
Background 
There is a dearth of information about how well this intervention is conducted in communities 
(implementation fidelity) as fidelity data are not included in routine program data. Therefore, this 
study measured the implementation fidelity of mass drug administration for onchocerciasis, 
lymphatic filariasis, and soil transmitted helminthiasis control, described factors affecting it, and 
determined the relationship between identified factors and implementation fidelity.  
Methodology 
A cross sectional survey was conducted in Nassarawa and Gezawa local government areas of 
Kano State, Nigeria, where a total 348 community directed distributors were interviewed. Scores 
were calculated by linearly combining responses obtained using Likert scales. Mean and median 
of implementation fidelity score were computed. Also, the mean of key determinants were 
calculated. Adjusted and unadjusted general linear regression models were then fitted to 
determine the relationship between implementation fidelity and identified determinants.  
Results 
The mean(SD) implementation fidelity score was 55.39(8.10) and median(IQR) was 56(60 - 49). 
Minimum implementation fidelity score obtained was 36 and maximum score was 72. The 
mean(SD) quality of delivery score, intervention complexity score, facilitation strategy score and 
participant responsiveness score were 16.77(2.74), 11.03(3.04), 8.83(0.99) and 4.62(0.52) 
respectively. Evidence of association between some factors and implementation fidelity score 
were found at p < 0.05. They include: intervention complexity (Adj Coef: -0.62(-0.93 to -0.30), 
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facilitation strategies (Adj Coef:-1.68(-3.05 to -0.32), participants responsiveness (Adj Coef: 
2.99(1.58 to 4.39), knowledge of NTD (Adj Coef: 0.75(0.36 to 1.13), CDD selection by local 
government staff (Adj Coef: 7.48(2.85 to 12.11), CDD who volunteered (Adj Coef: 8.38(4.59 to 
12.16) CDD with formal training in a health-related field (Adj Coef: 7.34(2.61 to 12.07), and 
CDD participation in other public health activities (Adj Coef: -6.16(-9.49 to -2.83).   
Conclusion 
This study demonstrated the feasibility of measuring implementation fidelity of mass drug 
administration. In addition, key determinants such as intervention complexity and participant 
responsiveness were found to be important factors affecting implementation fidelity and could be 
the target of future implementation strategies.  
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in a way to achieve what was intended.  
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Facilitation strategies  
These are support strategies that are used to optimize 
and standardize implementation fidelity. They 
include things like manuals and training etc.  
Participant 
responsiveness  
This is how communities respond to an intervention 
when they consider it as relevant.  
Community directed 
distributors  
These are community members assigned to conduct 
mass drug administration  
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CHAPTER ONE: INTRODUCTION 
 
1.0  INTRODUCTION OF CHAPTER 
 
This chapter gives an overview of neglected tropical diseases, and how mass drug administration 
is conducted in Nigeria to interrupt the transmission of those neglected tropical diseases amiable 
to preventive chemotherapy. Then context specific factors that affect mass drug administration 
exercises across various settings are discussed.  The concept of implementation fidelity and its 
conceptual framework is also discussed. The chapter ends with a conceptualization of fidelity 
assessment and its possible determinants based on existing literature and an adapted conceptual 
framework.   
1.1  BACKGROUND 
 
Neglected tropical diseases (NTDs) initially consisted of 17 chronic, debilitating infectious 
diseases as listed by the World Health Organization (1). They include Buruli ulcer, Chagas 
disease, dengue and chikungunya, guinea worm disease, echinococcosis, foodborne 
trematodiasis, human African trypanosomiasis, leishmaniasis, leprosy, lymphatic filariasis, 
onchocerciasis, rabies, schistosomiasis, soil transmitted helminthiasis, taeniasis, trachoma and 
yaws (1). Additionally, in 2016, mycetoma was recognized as a neglected tropical disease by the 
World Health Assembly (WHA)(1).  
Nigeria contributes the highest burden of soil transmitted helminthiasis, schistosomiasis, and 
lymphatic filariasis in sub Saharan Africa (2, 3). The country has an estimated 38 million cases 
of hookworm infection (3). This is only followed by the Democratic Republic of Congo which 
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has an estimated 31 million infections (3). Also, the estimated number of cases of 
schistosomiasis is 29 million, and about 106 million people are at risk of lymphatic filariasis (3).  
These diseases are most prevalent among people of low socio-economic status (4-6). NTDs have 
profound effect on health and wellbeing of individuals, as well as economic productivity (5, 7). 
For example, hookworm (one of the soil transmitted helminths) infection has been associated 
with anemia especially iron deficiency anemia in pregnant women and children (8, 9). Also, two 
independent studies in Tanzania and Niger Republic have shown that children with heavy worm 
infection (soil transmitted helminthiasis) suffer cognitive impairment, stunting and underweight 
(10, 11). Schistosomiasis has been implicated in painless hematuria, bladder and hepatic cancer 
(12-15). While, lymphatic filariasis can cause severe limb disability and consequently reduction 
in mobility which can aggravate poverty among farmers and their families (16) 
1.1.1 Control of neglected tropical diseases 
 
In order to mitigate the health and economic consequence of neglected tropical diseases, the 
WHO (World Health Organization) began spearheading efforts for prevention, control, 
eradication and elimination (17). Five main strategies for neglected tropical disease prevention 
and control have been recommended and they are as follows: preventive chemotherapy; safe 
water sanitation and hygiene, vector control, intensified case management and application of 
veterinary science in disease control in humans (7, 17, 18). 
1.1.2 Mass drug administration 
 
Preventive chemotherapy is the mainstay strategy for control of helminthic diseases such as; soil 
transmitted helminthiasis, schistosomiasis, onchocerciasis, and lymphatic filariasis, as well as 
bacterial diseases like trachoma, which are otherwise referred to preventive chemotherapy 
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neglected tropical diseases (PC-NTD) (19). In order to disseminate this strategy,  an intervention 
known as mass drug administration (MDA) is conducted in communities (19). MDA is a 
coordinated process where full dose of medicines are administered to all eligible members of a 
community (without contraindication) within the same period regardless of their disease status 
(19). This intervention became possible in 1987 when it was demonstrated that annual treatment 
with the drug; Mectizan (Ivermectin – MSD)  (for onchocerciasis), can clear microfilaria from 
the skin for up to six months (20, 21).  
In Nigeria where the prevalence of  preventive chemotherapy NTDs are high, mass drug 
administration is conducted in all 36 states including the federal capital territory in an integrated 
manner to interrupt transmission of multiple diseases at a time (2, 22). The policy document that 
directs integration is the national NTD masterplan; which is a context specific, multi-year 
comprehensive strategic framework developed with the support of World Health Organization 
(WHO)(22, 23). This masterplan contains the goals and the key performance indicators for the 
NTD control program in Nigeria (22). These key performance indicators are shown in Table 1.1 
and 1.2 (22).  
Since all states are endemic for more than one NTD,  national masterplan specifies the drug 
combination to be used (22). The following are accepted for use in Nigeria: ivermectin and 
albendazole, praziquantel and albendazole or mebendazole (22). Under special condition, triple 
combination of albendazole, ivermectin and praziquantel may be used(22).  
 
 
 
 4 
 
Table 1.1: National goals and Key Performance Indicators (KPI) for neglected tropical 
diseases 
Goals Objectives Key Performance 
Indicators (KPI) 
Preventive chemotherapy 
NTDs:  
Elimination of lymphatic 
filariasis, onchocerciasis, soil 
transmitted helminthiasis, 
schistosomiasis, and 
trachoma. 
1. To complete mapping 
of 4 of the NTDs by 
2013.  
2. To carry out 
preventive 
chemotherapy 
interventions in all 
endemic LGAs and 
communities.  
1. Number of LGAs 
completely mapped 
for these diseases 
2. Number of endemic 
LGAs implemented 
mass drug 
administration 
Source: Nigeria National NTD Masterplan (22) 
The step-by-step field implementation of mass drug administration exercises are guided by a 
WHO manual titled, “Preventive Chemotherapy in Human Helminths: Coordinated Use of 
Antihelminthic drugs in control interventions: A manual for health professionals and program 
managers” (23, 24). The manual specifies dosage of drugs, procedures like weighing or height 
measurement before drug administration, and eligibility criteria (23, 24).  
Mass drug administration are usually large scale interventions; covering diverse geographical 
areas, and involve complex delivery systems (21, 25). During field implementation, such 
interventions are prone to multiple context specific factors that can cause variation in quality of 
implementation across settings despite available evidence that the intervention can reduce 
morbidity from NTDs in the population (26-31). The contextual factors affecting implementation 
can be grouped into five and they include; community related factors, provider related factors, 
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type of innovation, organizational capacity, and training and technical support(31). Several 
researches have shown that poor quality of implementation causes implementation failure which 
can in turn leads to poor program outcome (32-34). This can discourage funders from investing 
further, and communities from accepting the intervention as effective (35). 
Table 1.2: Key Performance Indicators for preventive chemotherapy in Nigeria  
Disease specific goal Key Performance Indicator 
Trachoma 
elimination 
1. Number of LGAs completely mapped for Trachoma  
2. Number of trichiasis surgeries in endemic LGAs.  
3. Number of communities that have access to surgery  
4. Number of persons treated with Azithromycin.   
5. Number of Health facilities, LGAs and States reporting timely 
and monthly using the IDSR 003 Form.   
6. Reduction of disease transmission 
Soil transmitted 
helminthiasis 
elimination 
1. Number of LGAs completely mapped for STH  
2. Number of school aged children and other at risk population 
reached with deworming tablets in all endemic LGAs  
3. Number of symptomatic cases of STH managed using IMCI 
Strategy   
4. Number of Health facilities, LGAs and States reporting timely 
and monthly using the IDSR 003 Form 
Schistosomiasis 
elimination 
1. Number of LGAs completely mapped for Schistosomiasis.  
2.Number of symptomatic cases of Schistosomiasis managed using 
IMCI Strategy  
3. Number of school aged children and other at-risk population 
reached with deworming tablets in all endemic LGAs  
4. Number of Health facilities LGAs and States reporting timely  
and monthly using the IDSR 003 Form  
5.Reduction of disease transmission 
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Onchocerciasis 
elimination 
1. Number of endemic LGAs attaining a minimum of 80% therapeutic 
coverage.   
2.Number of LGAs with 100% geographical coverage   
3.Number of Health facilities, LGAs and States reporting timely  
and monthly using the IDSR 003 Form  
4.Reduction of disease transmission 
Lymphatic filariasis 
elimination  
1. Number of LGAs completely mapped for LF  
2. Number of endemic LGAs implementing MDA or PCT 
interventions.   
3. Number of hydrocele surgeries in endemic LGAs.   
4. Number of Health facilities, LGAs and States reporting timely and 
monthly using the IDSR 003 Form  
5.Reduction of disease transmission  
6. Number of LLINS jointly distributed with the Malaria Control 
Program. 
Source: Nigeria National NTD Masterplan (22) 
1.1.3 Implementation fidelity 
 
To enable the evaluation of implementation process, 8 conceptually distinct implementation 
outcomes with their definitions have been outlined (36). For practical reasons, these 
implementation outcomes are positioned before service and client outcomes to emphasize that 
implementation outcomes are the proximate determinants of other programmatic outcomes(37). 
Implementation fidelity is one of the eight implementation outcomes and is defined as “the 
degree to which an intervention was implemented as it was prescribed in the original protocol or 
as it was intended by the program developers” (30). Fidelity has its theoretical basis in RE-AIM 
(Research Effectiveness Adoption Implementation and Maintenance) and can be measured in 
early to mid-stage of implementation (30, 36).  
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Successful interventions have certain core implementation components (also knowns as 
implementation drivers) that are common to them (38). These core components were described 
in a framework by Fixsen and his colleagues (38). They include, staff selection, pre- and in-
service training, coaching, staff evaluation, program evaluation, facilitative administrative 
support and system intervention (38). Implementation fidelity provides information about level 
of implementation success upon the manipulation of these core components in different setting 
(38).    
In practice, fidelity elucidates how frontline providers were committed to the protocol, the 
amount of the program or sets of activities that were delivered and the quality with which they 
were delivered (30). Although implementation fidelity is not a new idea its only recently that 
program implementers had begun to operationalize its measurement in intervention evaluation 
(35, 39). Measuring implementation fidelity provides more information about the process of 
implementation – indicating whether an intervention was delivered as planned (36). Indeed, it 
has since been recommended that program design as well as evaluation frameworks include 
fidelity documentation as part of its core components (40).  
1.2  PROBLEM STATEMENT  
 
Integrated mass administration of two drugs; ivermectin and albendazole, for onchocerciasis, soil 
transmitted helminthiasis and lymphatic filariasis control is conducted yearly in communities in 
Kano State in line with the national NTD masterplan and the WHO helminthiasis preventive 
chemotherapy manual for program managers(23, 24). However, a dearth of knowledge about the 
fidelity of implementation of this intervention exist, as fidelity data are not routinely collected 
during monitoring and evaluation (22). In addition, context specific factors that affect 
implementation fidelity of this intervention in Kano State remains unknown.  
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Failure to measure implementation fidelity could potentially result in wastage of scarce financial 
and human resources invested in NTD programs. It could also decelerate the attainment of 
overall national elimination targets because implementation success or failure are not actively 
monitored across the various communities where this intervention is being conducted.  
1.3   JUSTIFICATION 
 
It is critical to study the implementation fidelity of mass drug administration as it would enable 
program implementers to objectively assess the quality of its implementation as well as factors 
that might affect it across different communities.  
The current level of political commitment to neglected tropical diseases control and prevention is 
an opportunity for Nigeria to meet WHO’s elimination targets for helminthic NTDs (41). To 
achieve this, implementation fidelity of mass drug administration needs to be tracked, 
documented and improved as fidelity is in the pathway between the intervention and program 
outcome (42).  
This research demonstrated the feasibility of measuring implementation fidelity of mass drug 
administration by adapting an already available conceptual framework which provides constructs 
within which implementation fidelity can be measured. In addition, the study explored some 
contextual factors that might affect implementation fidelity, and this can guide microplanning 
and policies relating NTD control.  
The multistage cluster sampling strategy used in this research is not only low cost and easier to 
implement, but is advantageous in providing information about level of implementation fidelity 
across various communities thereby highlighting variations in how mass drug administration is 
conducted. 
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The tool used for this research can easily be applied in other places where co-endemicity with 
onchocerciasis, lymphatic filariasis and soil transmitted helminthiasis exist. The research itself 
can be scaled up the entire state. 
 
1.4 RESEARCH QUESTION, AIM AND OBJECTIVES 
 
RESEARCH QUESTION: What is the implementation fidelity of community-based integrated 
mass drug administration for onchocerciasis, lymphatic filariasis and soil transmitted 
helminthiasis control in Kano State, and what factors affect it? 
AIM: To assess the implementation fidelity of community-based integrated mass drug 
administration for onchocerciasis, lymphatic filariasis, and soil transmitted helminthiasis in 
Nassarawa and Gezawa local government areas of Kano State and to describe the factors that 
affect it. 
OBJECTIVES 
1. To measure implementation fidelity of community based mass drug administration for 
onchocerciasis, lymphatic filariasis and soil transmitted helminthiasis in Kano State, 
Nigeria  
2. To describe factors affecting implementation fidelity of community based mass drug 
administration for onchocerciasis, lymphatic filariasis, and soil transmitted helminthiasis. 
3. To determine the relationship between identified factors and implementation fidelity. 
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1.5  LITERATURE REVIEW  
 
Database search covering full duration of publications was conducted to identify factors affecting 
implementation of mass drug administration in low and middle-income countries. The databases 
searched include; PubMed, Scopus, Web of Science, WHOLIS, and Africa Wide. The PubMed 
search strategy is attached as Appendix C. No date restrictions were placed on databases, and 
only articles published in English Language were considered.    
1.5.1  Factors affecting implementation of mass drug administration for control of 
neglected tropical diseases  
 
Several factors affect the implementation success of mass drug administration. The factors 
identified are grouped into organizational level factors, structural level factors and individual 
level factors to capture how they affect various implementation outcomes (43).  
1.5.1.1  Organizational level factors 
These are factors that represent employee morale, implementation culture or climate, and the 
leadership effectiveness of an institution, which could be a state or local government agency 
responsible for, or involved in implementing a health intervention such as mass drug 
administration (43). They include:  
a. High attrition: Organizational practices and processes that promote an accommodating 
work climate reinvigorates employee morale and trust which is necessary for successful 
implementation (31). Poor organizational practices lead to attrition of community 
directed distributors (CDD) or community health volunteers and this affects community 
based mass drug administration (44-48). High attrition rate is usually caused by lack of 
monetary incentives and inadequate supervision (44, 45, 47). This affects the 
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sustainability of NTD programs by leading to loss of funds invested in training CDD for 
mass drug administration exercises (45).  
b. Poor management of supply chain and logistics system: Many studies conducted in India, 
Sierra Leone, Nigeria and Uganda have identified poor drug supply mechanism by 
national medicines stores as a major factor affecting the implementation of mass drug 
administration exercises (45, 46, 48, 49). This results in drugs and other equipment like 
ivermectin rule not being readily available during mass drug administration exercises and 
this could affect implementation fidelity (43).  
c. Poor supervision and monitoring mechanism: Supervision is an important task of 
organizations responsible for implementation of health intervention especially when 
necessary resources like front line providers, items like drugs, and finances have been 
invested (31). Supervision is often inadequate during mass drug administration programs 
as highlighted by studies conducted in Kenya and India, and this could affect 
implementation fidelity (44, 47, 49, 50).  
d. Poor quality assurance following training: Government institutions responsible for 
implementing NTD control programs engage in training of health workers or community 
members assigned as community directed distributors before the mass drug 
administration exercise, however, there is a lack of quality assurance following these 
trainings (49). This means that knowledge assessments are not done, and training 
manuals are not evaluated for clarity, and simplicity (49).  This could affect the fidelity 
with which these trained personnel implement the intervention (43). In addition, long 
duration between training and implementation of MDA, as well as lack of re-training also 
affect quality of implementation (49).  
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1.5.1.2  Structural-level factors  
These are factors that reflect the broader community where mass drug administration is being 
conducted (43). They represent sociopolitical tendencies like misconceptions and sentiments, 
as well as role of household head and characteristics of the physical environment (43).  
a. Community misconception: Misconceptions and conspiracy theories can affect the 
overall implementation success of mass drug administration which can in turn affect 
program outcome (31). This was demonstrated in a study conducted during the Ebola 
virus disease (EVD) epidemic in Liberia where community members believed that the 
spread of the virus might be linked to mass drug administration (51).  In fact, hostilities 
towards health workers involved in mass drug administration was reported (51). In 
Western Kenya, conspiracy theories about the motive of MDA has been reported as a key 
factor reducing compliance (52).  
b. Positive sentiments: Positive sentiments toward mass drug administration are important 
for the implementation process and this can be stimulated through robust community 
engagement where community members and stakeholders are mobilized to participate in 
all activities (53, 54). In Fiji, involvement of traditional village forums in a mass drug 
administration program for lymphatic filariasis control was found to be a positive 
predictor of adherence in a multivariate analysis (OR=1.78 95%CI (1.04 – 3.05)(55). 
c. Characteristics of location: Urban-rural variation affects the quality of implementation of 
mass drug administration and has been identified as an important determinant of 
coverage; which is a construct of implementation fidelity, and compliance (56-58). Poor 
attitude of health workers and inadequate social mobilization were associated with poor 
coverage and compliance in urban areas (56).  
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d. Migration: Inter border movement and migration patterns have also been found to impact 
the implementation of mass drug administration (46, 59). This is because it is often 
difficult to ascertain the actual number of adults who are resident of an area that have 
been reached with the medicines (59).  
e. Poor household participation: The impact of mass drug administration is reduced when 
household participation is poor because of there will be high number of untreated people 
after the exercise (60). Some of the main reasons for this poor household participation 
include; household head non-participation, increased size of household, higher time to 
source of water among members of a household and non-inclusion of household head in a 
previous exercise (60).   
f. Health education: Inadequate pre-MDA health education exercises are implicated when 
fear of drug side-effects continues to determine low compliance or uptake of medicines 
during mass drug administration campaigns in communities (47, 48, 50, 56, 61, 62). In 
West Bengal, of the 683 people who were eligible to receive treatment for lymphatic 
filariasis, although 98.8% of them received the medications, 5% admitted to not taking 
the drug due to fear of side effects (56). In another 5 year review conducted in India, 
noncompliance was above 40% in the population covered on account of fear of adverse 
drug reactions (61).  
1.5.1.3  Individual level factors  
These represented aspects of the front line provider who implement the intervention (43). They 
reflect knowledge, skills, attitude and perceptions of the providers (43).  
a. Gender dynamics: The gender of a community directed distributor is an important factor 
in the implementation of mass drug administration programs as a study in Tanzania has 
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associated it with performance of community health workers participating in mass drug 
administration exercise (63). It was found that time per interaction in areas with only 
female workers was higher compared to areas with only male or mixed workers 
(104.9seconds, 80.1 seconds, and 70.1 seconds respectively) (P=0.01) (63). Furthermore, 
female workers at sites with only females made more statements per interaction than 
males at sites with only male community workers (15.9 and 11.4 respectively) (P=0.02) 
(63). However, at sites where males and females were mixed, males spoke more than 
women (6.8 and 5.9 statements per interaction respectively) (P=0.01) (63). 
b. Relationship between drug distributors and target population: Intervention dissemination 
by individuals that have good background relationship with community members are 
more likely to be successful (59, 61). In an attempt to increase coverage rate in an urban 
area in India, a group of community health workers that have long standing relationship 
with the community were engaged to conduct mass administration of drugs for lymphatic 
filariasis control (61). It was found that 33% of people who accepted the medicine did so 
because they were familiar with the individuals (61).  
1.5.2 Implementation fidelity framework  
 
Several frameworks for implementation fidelity such as the Department of Veteran Affairs 
Quality Enhancement Research Initiative, Behavior Change Consortium Framework for 
Treatment Fidelity exist (64, 65). However, a more elaborate and recent framework known as the 
Conceptual Framework for Implementation Fidelity was proposed by Christopher Carroll and his 
colleagues (66). This framework was developed following a systematic review of literature on 
implementation fidelity and it encompasses all the components of implementation fidelity and 
their interrelationship (66) 
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In this research project, which measured implementation fidelity and examined context specific 
factors affecting implementation fidelity in Kano State, Nigeria, the contextual framework for 
implementation fidelity by Carroll was adapted to include some of the factors identified above 
(66). This framework posits that implementation fidelity is in the pathway between an 
intervention and  program outcome and went further described fidelity in terms of four constructs 
namely; duration, frequency, coverage and content (66). These four constructs are together 
referred to as adherence(66). The framework asserts that adherence is the bottom line measure of 
implementation fidelity and should be considered as a unidimensional variable (66). Therefore if 
an intervention adheres to the content, frequency, duration, and coverage as indicated in the 
original manual, model or program design, it is said to be implemented with high fidelity (66).  
Content is the “active ingredient” that an intervention seeks to deliver (66). For mass drug 
administration, content refers to drug combinations used, the drug dosages, eligibility for 
treatment, and application of exclusion criteria in communities(23, 24). The other three 
constructs of adherence namely; frequency, coverage and duration are collectively known as 
dose (66). Dose of a mass drug administration program refers to whether the intervention was 
delivered for as often as planned, to all eligible members of a community and for as long as was 
indicated in the original program design or model (66). Nevertheless, a high level of adherence 
depends on the determinants or moderators of implementation fidelity (66).  
Four determinants of implementation fidelity were specified in this framework and they include 
intervention complexity, facilitation strategies, quality of delivery, and participant 
responsiveness (66).  
Intervention complexity is concerned with the description of the intervention, whether it is 
simple or complex (66). This is important for mass drug administration exercises which utilizes 
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manuals to guide community directed distributors in the field (22). If the description of the 
intervention is simple in those manuals, mass drug administration is more likely to be conducted 
with high fidelity (66, 67).  
Facilitation strategies, is concerned with the type of support strategy which could range from 
training, provision of manuals and job aids, to logistics and supply chain systems (66). When 
such support strategies are available during health interventions like mass drug administration, a 
high implementation fidelity is likely to be attained (24, 68).   
Quality of delivery is concerned with how appropriately an intervention is delivered to achieve 
the desired goal (66). Since administration of drugs such as ivermectin and albendazole require 
height and weight measurement, availability of instruments such as ivermectin rule for measure 
height and weighing scale for measuring weight of community members is necessary for 
implementation of the intervention (24). Also, to ensure quality delivery, the community should 
be adequately sensitized as indicated in the WHO guideline (24).  
Participant responsiveness, is concerned with how cooperative community members were during 
an intervention which is a function of innovation fit and community sensitization (66). If a 
community perceives diseases such as helminthiasis, onchocerciasis, or lymphatic filariasis as a 
major health problem, they are more likely to cooperate with community directed distributors 
during mass treatment exercises (66).  
1.5.3  Implementation fidelity of mass drug administration in Kano State and its 
determinants 
 
To measure implementation fidelity of mass drug administration in this study, all the 4 constructs 
of adherence (content, coverage, frequency and dose) in the original conceptual framework were 
used (24, 66). Content measured the active component of the intervention like use of albendazole 
and ivermectin in combination, dose of albendazole, height measurement before administering 
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ivermectin, calculating total doses required with provision for loss and wastage, and eligibility 
criteria (24). While, coverage, frequency, and duration assessed whether every eligible member 
of the community was covered, MDAs are conducted yearly, and MDA lasted within the 
specified numbers of days respectively (24).  
Some organizational, structural and individual level factors that could affect mass drug 
administration as identified from previous studies were combined with the four determinants of 
implementation fidelity already specified in the conceptual framework for implementation 
fidelity to give the complete list of determinants considered in this study (43, 66).  
The determinants were grouped into key determinants, other determinants and background 
characteristics. The key determinants were the determinants from the conceptual framework of 
implementation fidelity (66). The included quality of delivery, intervention complexity, 
facilitation strategies, and participants responsiveness (66). Facilitation strategies reflected 
organizational level factors identified from review of previous studies like training, and 
availability of manuals and other job aids (49). Quality of delivery included assessment of 
supportive supervision by state and local government authorities as well as adequate supply of 
drugs and other equipment required for proper implementation (44, 47, 49, 50). These also 
reflect organizational level factors. Intervention complexity assessed the simplicity or 
complexity of the manual and process of conducting mass drug administration in the field, while 
participant responsiveness gauged how cooperative community members were during mass drug 
administration.  
Other determinants included incentives, knowledge of NTDs and how community directed 
distributors participating in mass drug administration are selected. Incentives was included as a 
determinant because previous studies had identified it as a cause of CDD attrition (44, 45, 47). It 
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was deemed important to assess whether it affects implementation fidelity as well. However, 
knowledge of NTD among CDDs and selection of CDDs were included for conceptual reasons. 
Although incentives and selection of CDD can be classified as organizational related factors, 
knowledge is an individual level factor.  
Background characteristics like sex was included based on findings from a previous literature 
that related gender of CDD to level of interaction during mass drug administration exercise (63). 
Location characteristics was also included because previous studies have demonstrated that rural 
urban variation affects implementation (56-58). Other background factors were included for 
conceptual reasons. Location characteristics is a structural level factor while the rest are 
individual level factors (43).   
The conceptual framework of implementation fidelity was chosen for adaptation because it has 
clearly defined constructs of fidelity and its determinants which eases conceptualization of 
fidelity and applicability in my research context (66).  
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The conceptual framework for this study is shown in Figure 1.1 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Conceptual framework of determinants of implementation fidelity of mass drug 
administration adapted from Carroll’s Framework.  
 
 
 
 
 
 
 
 
 
Implementation 
fidelity of MDA: 
content, 
frequency, 
coverage and 
duration 
Key determinants of implementation fidelity:  
➢ Intervention complexity 
➢ Quality of delivery  
➢ Participant responsiveness  
➢ Facilitation strategies  
Other determinants of implementation fidelity:  
➢ Incentives 
➢ Selection of community directed 
distributors  
➢ Knowledge of NTD 
 
Background characteristics of community drug 
distributor: 
Age, sex, marital status, occupation, location, 
highest level of education, stable income, formal 
health training, participation in other public 
health activities.  
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CHAPTER TWO: METHODOLOG Y 
 
2.0  INTRODUCTION 
 
In this chapter, the study design, study site and target population are described including 
justification for choosing the study site. Also, data collection procedure is discussed in detail. 
Other sections include variables, analysis plan, statistical analysis and ethical consideration.  
2.1  STUDY DESIGN 
 
A cross sectional survey design was used to assess implementation fidelity and its determinants 
(69).   
2.2  STUDY SITE 
 
The survey was conducted in 2 local governments areas; Nassarawa (urban) and Gezawa (rural) 
local government areas of Kano State, located in north west Nigeria (70).  
Nassarawa local government is one of the eight urban local governments areas (LGA) in Kano 
State (located in senatorial district zone A) with an area of 35km2 (70, 71). According to the 2006 
National Population and Housing Census, the population was 596,411 (323740 males and 
272671 females) with an annual population growth rate of 3.1% (70).  
In this LGA, 7,803 households have access to pipe borne water (70). 26,212 households have 
access to water closet toilet facility and only 417 use nearby bush (70). Only 18.4% of 
households do not have access to a telephone (70).  
While Gezawa local government is one of the 36 rural local government areas in Kano State 
(also located in senatorial district zone A) with an area of 355.481km2 (70, 71). The population 
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of Gezawa according to the 2006 National Population and Housing Census is 282, 328 (143,380 
males and 138,948 females) with an annual population growth rate of 3.1% (70). In this LGA, 
only 1889 households have access to pipe borne water (70). 2311 have access to water closet 
toilet facility, and 578 household use nearby bush (70). About 31.6% of households do not have 
access to a telephone (70).  
Each local government is made up of 11 administrative wards each and are all endemic for 
helminthic neglected tropical diseases (22, 72). A total of 2720 CDDs conduct mass drug 
administration with Ivermectin and Albendazole in both local government areas.  
2.3  STUDY POPULATION 
 
Community directed distributors that have conducted community based, integrated mass drug 
administration with ivermectin and albendazole in Gezawa and Nassarawa Local Government 
Areas of Kano State, Nigeria.  
2.4  SAMPLING 
 
This comprises of sampling technique and sample size calculation. 
2.4.1 Sampling technique 
 
A multistage cluster sampling technique which utilizes an existing structure in the state was used 
because of its relatively cheaper, easier to conduct, and more time efficient (73, 74). In Nigeria, 
enabling laws provides for a territorially demarcated local government area to exist within states 
(75, 76). Within each local government area, there is a further subdivision into units called wards 
(75).   
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In this study, these wards were considered as clusters (primary sampling units). Twelve wards 
were randomly selected from both local government area (six wards each) using a 
comprehensive and mutually exhaustive list of wards obtained from 2006 National Housing and 
Population census data as published by the National Population Commission (77). For Gezawa 
Local Government area, the list of all 11 wards were entered in Microsoft Excel 2016 and 
numbered accordingly. Then MS Excel random number generation function command; 
RANDBETWEEN (1,11) was used to choose six wards from the local government. The same 
procedure was then repeated for Nassarawa local government area. The wards selected were as 
follows: Kaura Goje, Giginyu, Tudun Murtala, Tudun Wada, Gawuna, and Gama for Nassarawa 
LGA, and Ketawa, Sararin Gezawa, Jogana, Tumbau, Wangara, and Babawa for Gezawa LGA. 
Secondly, from within each cluster (or primary sampling unit), community directed distributors 
(CDD) were then randomly selected from a list of CDD in each ward as provided by the local 
government NTD focal person. A community directed distributor was defined as someone who 
has participated in a community based mass drug as a frontline provider of preventive 
chemotherapy to community members.  
Inclusion criteria include: CDD resident in the community at time of data collection and must 
have participated in the 2016 mass administration of Ivermectin and Albendazole.  
Exclusion criteria include: CDD who were absent or had relocated from the study site at time of 
data collection.   
2.4.2 Sample size 
 
The minimum sample size for this study was calculated using StatCalc function in Epi Info. An 
expected frequency of 50% was presumed because there were no previous studies that reported 
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the prevalence of implementation fidelity of MDA. Design effect was taken into consideration 
because of cluster sampling technique used. However, a design effect of 1 was used for 
feasibility and logistical reasons. Given that there are 2720 CDDs in both local government 
areas, at 95% confidence level, precision of ±5%, and a design effect of 1(one) yielded minimum 
sample size of 348. Power was set at 80%. Given the selection of n = 12 clusters, we selected m 
= 29 community directed distributors per cluster.    
2.5  DATA COLLECTION 
 
2.5.1  Questionnaire 
 
A data collection tool (questionnaire) was developed in line with the conceptual framework of 
this study to collect information on background information of community directed distributors, 
their knowledge of neglected tropical diseases, implementation fidelity of mass drug 
administration and factors affecting implementation fidelity of mass drug administration. 
Responses to questions covering knowledge, implementation fidelity and factors affecting 
implementation fidelity were based on 5-point Likert scale with response ranging from strongly 
agree to strongly disagree. 
The four sections contained in the tool are as follows:  
background characteristics of participants which contain questions on demographic, 
socioeconomic, and past experience of respondent like participation in other public health 
activities, as well as working as a health worker; level of knowledge of community drug 
distributors which elicited responses to assess knowledge based on participant responses to full 
meaning of NTD, whether NTD are diseases of public health importance, mass drug 
administration in schools, and mass drug administration on communities; implementation of 
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mass drug administration by community directed distributors which contained questions on 
type of medicines used in mass drug administration, dosing of medicines used in mass drug 
administration, how to administer the medicines, eligibility criteria and contraindications; and 
factors affecting implementation fidelity such as quality of delivery, intervention complexity, 
facilitation strategies, participant responsiveness, CDD selection, and availability of incentives. 
The detailed questionnaire is attached as Appendix D.  
Validity of this tool was ensured by evaluating drafted questionnaire for fluency, adequacy and 
clarity in several meetings with my supervisors. Drafts were then corrected and revised again 
with supervisors until it was deemed appropriate. The tool was then pretested in Tarauni Local 
Government Area (which is a different location from my study area) to determine the feasibility 
as well as appropriateness of question format, wording and order from a lay perspective. The 
participants of the pretest exercise were asked to give their opinions about the questions and to 
state if they felt any question should be modified. All participants of the pretest said the 
questions were simple and clear. 
2.5.2  REDCap database 
 
Research Electronic Data Capture (REDCap) was used to design the database for this 
project(78). The online designer function of the web application was used to design the data 
forms. On each form, fields were added, and field type specified. Field labels were the questions 
as contained on the questionnaire while variable names were entered manually. Auto naming of 
variables was disabled to specify more descriptive variable names. Fields like participant ID, 
age, monthly income were text fields, while a combination of radio and drop down were used for 
other fields like name of local government, ward name, occupation, level of education, type of 
health training. Only radio was used for the fields that had Likert scale. Validation was used to 
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specify that only an integer may be used for age, and minimum age of 18 was specified for 
ethical reasons. Calculation syntax was used for fields that computed scores. Branching logic 
was used for questions that appear under certain conditions. For example, a “parent question” 
which contains “others (please specify)” had a branching logic added so that respondent can 
specify the answer in a “child/dependent question”. Logic builder was used to add the condition 
to option that will result in appearance of the child question. HTML formatting was added to the 
forms. Some of the HTML codes used are as follows: <strong> </strong> where bold was 
required, and <em> </em> where italics was required.  
2.5.3  Advocacy  
 
Advocacy visits were conducted to inform and seek verbal permission of government 
stakeholders and community gatekeepers before commencing data collection.  
At state government level, a visit was paid to the director of public health at the state ministry of 
health to inform his office of the planned research project. The aim and objective of the research 
was shared with the director and his team. Also, the state NTD coordinator was briefed on the 
planned research project.  
At local government level, the zonal primary health care director was informed of the research 
project after which the local government NTD focal persons for Nassarawa and Gezawa LGA 
were notified of the planned research work.  
At community level, traditional leaders are the gatekeepers. They include “dagachi” and 
“hakimi” which mean district head and ward head respectively. Advocacy visits were paid to the 
“hakimai” (plural of “hakimi”) of both local governments to inform them of the research project 
after which they informed the various “dagatai” (plural of “dagachi”) in their wards. In Gezawa, 
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the dagatai assigned town criers to notify all community directed distributors in the selected 
wards of the planned data collection exercise. While in Nassarawa, the dagatai sent messengers 
to inform all community directed distributors of the planned activity.   
2.5.4  Training of data collectors 
 
Data collectors were trained during a one-day orientation exercise where a discussion on 
research ethics, data collection tool and use of mobile devices were held. Four data collectors (3 
males, 1 female) were recruited for this research and they all participated in the training. They all 
had a minimum of secondary school leaving certificate and previous experience using mobile 
devices for data collection. 
2.5.5  Field work 
 
Data collection commenced on 1st February and ended on 16th February 2017. The tool used for 
data collection was a structured, interviewer administered questionnaire on a mobile tablet 
device. It was translated into Hausa language (local language) when necessary during data 
collection.  
2.6  DATA MANAGEMENT 
 
Since data was collected using REDCap mobile application, quality assurance was done by pre-
populating some variables to have default values using key/value pairs. URL encoders were used 
to convert string to an encoded string. And branching logic were used for questions that need to 
be concealed until a response is provided for a prior one. After completion of data collection, the 
data file was exported from REDCap to STATA 14.1 for analysis. A priori, it was decided that 
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respondents with any missing value in the variables used to compute the outcome variable will 
be excluded, however, this didn’t occur in the research.  
2.7  VARIABLES 
 
Outcome variable: Implementation fidelity (continuous variable) 
Explanatory variables: The explanatory variables are presented in Table 2.1.  
Table 2.1: List of explanatory variables  
Variables Type Coding 
KEY DETERMINANTS OF IMPLEMENTATION FIDELITY 
Quality of delivery Continuous variable  - 
Intervention complexity Continuous variable - 
Facilitation strategies  Continuous variable - 
Participants responsiveness Continuous variable - 
OTHER DETERMINANTS OF IMPLEMENTATION FIDELITY 
Knowledge of NTD Categorical variable  “1” = adequate, “0” = 
inadequate 
Incentives Categorical variable  “0” = no, “1” = yes 
Selection of CDD Categorical variable  “1” = community, “2” = local 
government staff, “3” = 
volunteered 
BACKGROUND CHARACTERISTIC OF RESPONDENTS 
Age group Categorical variable “1” = less than 25, “2” = 25 – 
29, “3” = 30 – 34, and “4” = 35 
and above. 
Sex Categorical variable “1” = male, “2” = female 
Marital status Categorical variable “0” = never married, and “1” = 
ever married 
Occupation  Categorical variable “1” = No occupation “2” = 
student “3” = health work “4” = 
teaching “5” = farming 
Location characteristics Categorical variable “1” = rural, “2” = urban 
Highest level of education  Categorical variable “1” = primary education and 
below, “2” = secondary 
education and “3” = tertiary 
education 
Stable income  Categorical variable “1” = yes “0” = no 
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Formal training in health-related 
field 
Categorical variable “1” = yes “0” = no 
Participation in other public 
health activities  
Categorical variable “1” = yes “0” = no 
2.8  DATA MANAGEMENT  
 
Outcome variable 
The scale reliability coefficient (Cronbach’s alpha) was computed to assess if the 15 items on the 
questionnaire provide a reliable measure of the same latent variable; implementation fidelity 
(79). The correlation between the 15-item scale and all other possible 15-item scales measuring 
implementation fidelity was 0.79 (i.e. Cronbach’s alpha = 0.79). Cronbach’s alpha of each of the 
15 items were above 0.7 as well (See Table B.2 in the appendix). Since this reliability coefficient 
is acceptable, implementation fidelity score was obtained by summing up all the responses (Min 
= 15, Max = 75).   
Explanatory variables  
Key determinants: Quality of delivery score, intervention complexity score, facilitation 
strategies score and participant responsiveness score had five (5), three (3), two (2) and one (1) 
items respectively. Responses were rated on a 5-point Likert scale ranging from 1 (strongly 
disagree) to 5 (strongly agree). The scale reliability coefficient (Cronbach’s alpha) for quality of 
delivery and intervention complexity was found to be 0.40 and 0.74 respectively. To prevent 
underestimation of true reliability, the Cronbach’s alpha of facilitation strategy, and participant 
responsiveness were not calculated because they were 2-item scale and 1-item scale respectively 
(80).  
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Scores were calculated by summing responses (quality of delivery score (Min = 5, Max = 25), 
intervention complexity score (Min = 3, Max = 15), facilitation strategies score (Min = 2, Max = 
10) and participant responsiveness score (Min = 1, Max = 5)).  
Other determinants: Incentives and selection of community directed distributors were used as 
collected. Knowledge was assessed using 4 – item questions with responses based on 5 – point 
Likert scale. Knowledge score was then computed by adding the responses obtained. 
 Background characteristics: Age which was collected in years and was converted into a 
categorical variable; age groups. Age groups include: less than 25, 25 – 29, 30 – 34, and 35 and 
above. Marital status was further re-categorized into 2 groups (never married, and ever married) 
because none of the respondents were separated or divorced and only 11 participants were 
widowed. Level of education was also re-categorized into 3 groups (primary education and 
below, secondary education and tertiary education) because only 13 respondents had no formal 
education and 19 had primary education. For regression analysis, occupation was re-categorized 
into 2 groups (non-health workers and health workers). All other background characteristics 
variables were used for analysis as collected.  
2.9  STATISTICAL ANALYSIS  
 
All statistical analysis for this research project was done using STATA Statistics/Data Analysis 
Software version 14.1(STATACorp, Lakeway Drive, College Station, TX, USA). None of the 
respondents were excluded from analysis.  
In order to obtain robust estimates which accounted for the multistage cluster sampling used in 
this research, svyset command with probability weight, and finite population correction (FPC) at 
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every stage of sampling was specified (81, 82). Then, svy command was used as the prefix for all 
descriptive, univariate and multivariate analysis (81, 82).   
 
Objective One: To measure implementation fidelity of community based mass drug 
administration for onchocerciasis, lymphatic filariasis and soil transmitted helminthiasis  
The measurement of Implementation fidelity was operationalized according to the constructs 
(content, coverage, frequency and duration) specified in the conceptual framework. All four 
constructs were covered in a 15-item questionnaire. Rating of the items were based on 5-point 
Likert scale ranging from (1) strongly disagree to (5) strongly agree with higher scores signifying 
increasing fidelity. 
Composite score of implementation fidelity was obtained for each respondent. The mean and 
standard deviation as well as the median and interquartile range were calculated.  In addition, 
implementation fidelity score was ordered and divided into three parts to produce tertiles. First 
tertile represented low score, second tertile represented moderate score, while the third tertile 
represented high score. The mean implementation fidelity score for each tertile was calculated. 
Box plots of the overall implementation fidelity score and the implementation fidelity score for 
each tertile was drawn.  
Factor score (latent score) of implementation fidelity was obtained using exploratory factor 
analysis (83). Since the Kaiser-Meyer-Olkin Measure of Sampling Adequacy of 0.83 was 
obtained, a correlation matrix was fitted (84). The output of this correlation was used to perform 
factor analysis (84). Kaiser rule and Scree plot was used to support the decision to retain factors 
with eigen value greater than one (85). The retained factors were rotated using a varimax 
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orthogonal rotation to produce uncorrelated factors, which were then used to obtain factor scores. 
Output of exploratory factor analysis is attached in the Appendix (Table B.3 – 10).  
 
Objective two: To describe factors affecting implementation fidelity of community based mass 
drug administration for onchocerciasis, lymphatic filariasis, and soil transmitted 
helminthiasis. 
 For key determinants: Mean and standard deviation of quality of delivery score, intervention 
complexity score, facilitation strategies score, and participants responsiveness score were 
calculated. 
For other determinants: The frequencies and percentages of other determinants (incentives, 
selection of CDD, and knowledge) were calculated. In addition, the implementation fidelity 
score for each of their categories was calculated.  
For background characteristics: Age, sex, marital status, occupation, highest level of 
education, stable income, formal training in health-related field and participation in other public 
health activities were summarized using frequency and percentages. The mean (and standard 
deviation) of implementation fidelity score for each of the categories of these variables were then 
calculated. The results were presented using tables.  
Objective three: To determine the relationship between identified factors and implementation 
fidelity.  
 Adjusted and unadjusted coefficients of two models were computed. For Model 1, unadjusted 
coefficients (with their 95% confidence intervals) were obtained by fitting survey linear 
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regression to determine whether each of the key determinants; quality of delivery score, 
intervention complexity score, facilitation strategy score and participants responsiveness score 
predicted implementation fidelity score. The following linear regression equation was used y = 
β0 + β1xi + εi (β0 and β1 were model parameter and εi was error term). Statistical significance was 
at p < 0.05. Scatter plots were used to demonstrate linearity. Then adjusted coefficients (with 
their 95% confidence intervals) were obtained by fitting survey linear regression with all the sets 
of key determinants (quality of delivery score, intervention complexity score, facilitation strategy 
score, and participants responsiveness score) included in the model. The decision to include all 
variables in this model was for conceptual reasons. The following linear regression equation was 
used y = β0 + β1xi + …. + βkxki + εi (β0, β1, β1 were model parameter and εi was error term). 
Statistical significance was at p < 0.05.  The multiple correlation coefficient of determination 
(R2) of the model was reported.  Multicollinearity of the predictor variables (quality of delivery 
score, intervention complexity score, facilitation strategy score, and participants responsiveness 
score) were assessed using survey correlation before fitting the model.  For sensitivity analysis, a 
univariate ordered logistic regression model was fitted using implementation fidelity categorized 
into tertiles and key determinants.  
Similarly, for Model 2, unadjusted coefficients (with their 95% confidence intervals) were 
obtained by fitting survey linear regression to determine whether each of the explanatory 
variables; quality of delivery score, intervention complexity score, facilitation strategy score, 
participants responsiveness score, knowledge score, incentives, selection of community directed 
distributors, age group, sex, marital status, occupation, location characteristics, highest level of 
education, stable income, formal training in health-related field, and participation in other public 
health activities predicted implementation fidelity. Subsequently, adjusted coefficients (with 
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their 95% confidence intervals) were obtained by fitting survey linear regression with only the 
explanatory variables that were significant at p < 0.05, while holding all the key determinants 
(quality of delivery score, intervention complexity score, facilitation strategy score, and 
participants responsiveness score) and location characteristics constant in the model. The 
multiple correlation coefficient of determination (R2) of the model was reported.  
Multicollinearity of all explanatory variables (quality of delivery score, intervention complexity 
score, facilitation strategy score, participants responsiveness score, knowledge score, selection of 
CDD, occupation, training in a health-related field, participation in other public health activities, 
and location characteristics) included in the multiple regression model were assessed using 
survey correlation before including them in the fitted model.   
2.10  ETHICAL CONSIDERATION 
 
The study was conducted in line with current research ethical guidelines(86, 87). The study 
protocol was submitted to both Wits Human Research Ethics Committee (HREC - Medical) and 
the ethics committee of Kano State Ministry of Health for approval. Kano State Ministry of 
Health gave ethical approval in a letter dated 14th November 2016 with reference number 
MOH/Off/797/T.I/218 (attached as Appendix H). While Wits HREC (Medical) gave 
unconditional approval on 13th January 2017 with clearance certificate no: M1611117 (attached 
as Appendix I).  
To minimize risk during data collection, an information sheet (attached as Appendix E) and 
informed consent form (attached as Appendix F) were given to all study participants. The 
information sheet was read and explained to all study participants as well as the consent form. 
Participants then signed and returned the consent form to the field data collector. All participants 
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were clearly informed that they can leave the study at any point or choose not to answer any 
question if they so wish. Participants were also reassured that if they choose to leave the study or 
decide not to answer any of the questions, their responsibility as community directed distributors 
would not be affected. No identifying variable like name was collected to maintain anonymity of 
respondents. The study posed minimal risk to participants. All data were safely stored on Wits 
University database and only the principal investigator had access to it.  
2.11:  LIMITATIONS OF THE STUDY METHODOLOGY 
 
1. Small sample size: A design effect of 1 was used to calculate the minimum sample size for 
logistical reasons. This relatively small sample size affected the number of variables that were 
included in the model.  
2. Generalizability and applicability: The extent to which the results of this present research can 
be generalized to the entire state is limited as data was only collected in 2 of the 44 local 
government areas in Kano State.  
Nassarawa is one of the most cosmopolitan local government areas in the state. There is also 
high turnover of CDDs in this local government, as previously trained CDDs often move to other 
places. Also, the traditional leadership institution in this local government is not as established as 
Gezawa which is a more rural area. These contextual features have effect on measurement.  
Also, care should be taken when applying the tools used in this study in other settings. It is 
advisable to validate this tool before use.  
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2.12  DISSEMINATION  
 
This study was presented at Bayero University Kano, Kano State, Nigeria during a research 
seminar forum. The audience was postgraduate students and faculty members from the Center 
for Infectious Disease Research (CIDR) and Community Medicine Department of the university. 
Findings from this study were also presented to the director of public health at the Ministry of 
Health in Kano State during a dissemination meeting. In addition, the study was presented during 
a workshop organized by the special program for research and training in tropical diseases 
(WHO/TDR) in Geneva, Switzerland. Manuscripts will be developed and submitted for peer 
review publications. The compiled research report will be submitted to the library of University 
of the Witwatersrand, Johannesburg for public use.  
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CHAPTER THREE: RESULTS  
 
The results of statistical analysis conducted using data obtained from 348 community directed 
distributors are presented here. The presentation of findings follows each of the research 
objectives. Tables and graphs are used to illustrate findings.   
3.1   MEASURING IMPLEMENTATION FIDELITY OF 
COMMUNITY BASED MASS DRUG ADMINISTRATION FOR NTD 
CONTROL 
 
Composite score: The minimum implementation fidelity score is 36 (48%), while the maximum 
score is 72 (96%). The mean implementation fidelity score for all study participants is 55.39 with 
standard deviation of 8.10. The distribution of the scores are normal since the mean and median 
are close (median is 56). CDDs in the first tertile have a lower mean implementation fidelity 
score compared to those in the second and third tertiles. Other descriptive features are presented 
in Table 3.1.  
Table 3.1: Descriptive statistics of implementation fidelity score of mass drug 
administration by community directed distributors in Kano State, Nigeria.  
Variable Range 
Number of 
observations Mean (SD) Median(IQR) 
Overall Implementation fidelity 
score  36 - 72 348 55.39(8.10) 56(49 - 60) 
Tertile 1 36 - 52 118 46.12(3.79) 47(44 - 49) 
Tertile 2 53 - 59 121 56.46(1.96) 57(55 - 58)  
Tertile 3 60 - 72 109 64.24(4.12) 63(61 - 68) 
 
The box plot presented in Figure 3.2 shows that the size of the boxes varies according to tertile 
as the range of score within each tertile differ from each other. 
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Figure 3.1: Box plot of implementation fidelity score 
 
Figure 3.2: Box plot of implementation fidelity score by tertile 
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Factor score: Eight items loaded on factor 2 as shown on Table B.8. The mean and standard 
deviation of the latent score obtained for factor 2 is 8.68 and 2.68 respectively. Descriptive 
statistics of other factors are presented in Table 3.2.  
Table 3.2: Descriptive statistics of latent score of implementation fidelity of mass drug 
administration by community directed distributors in Kano State, Nigeria. 
Factors Frequency Mean(SD) 
Factor 1 348 3.16(1.49) 
Factor 2 348 8.68(2.68) 
Factor 3 348 -1.04(3.18) 
 
3.2  DESCRIPTION OF FACTORS AFFECTING IMPLEMENTATION 
FIDELITY OF COMMUNITY BASED MASS DRUG ADMINISTRATION 
IN KANO STATE 
 
3.2.1 Description of key determinants affecting implementation fidelity of community based 
mass drug administration in Kano State, Nigeria  
 
Although the maximum quality of delivery score obtained is 22 (out of 25), the mean quality of 
delivery score is 16.77 (with standard deviation of 2.74). Similarly, a maximum score of 15 (out 
of 15) for intervention complexity with mean score of 11.03 (standard deviation of 3.04) was 
obtained.  The distribution of the scores obtained are normal as their means and medians are 
almost equal. The descriptive statistics for other key determinants are presented in Table 3.3.  
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Table 3.3: Descriptive statistics of key determinants of implementation fidelity of mass 
drug administration in Kano State, Nigeria 
Variables  CDD (348)  Percentage Min/Max Score Mean(SD) 
Median 
 (IQR) 
Quality of delivery score 348 100 10 - 22 16.77(2.74) 17(15 - 18) 
      
Intervention Complexity  348 100 3 - 15 11.03(3.04) 12(9 - 14) 
      
Facilitation strategies  348 100 5 - 10 8.83(0.99) 9(8 - 10) 
      
Participants 
Responsiveness 348 100 3 - 5 4.62(0.52) 
 
5(4 - 5) 
      
IF = Implementation fidelity, SD = Standard Deviation, CDD = Community directed distributor  
3.2.2 Description of other determinants and background characteristics affecting 
implementation fidelity of community based mass drug administration in Kano State, Nigeria  
 
Of the 348 CDDs interviewed, only 37% have adequate knowledge of NTD. Among those with 
inadequate knowledge, their mean implementation fidelity score is 53.66 while those with 
adequate knowledge have a mean implementation fidelity score of 58.22. Over 80% of the CDDs 
interviewed were selected by their community members as oppose to only about 5% that were 
selected by a local government staff. However, the mean implementation fidelity score among 
those CDD selected by community members is 53.38 while those selected by local government 
staffs have a mean implementation fidelity score of 65.65.   
Among those aged 25 – 29, their mean implementation fidelity score is 56.58, while those aged 
above 35 years have a mean implementation fidelity score of 54.29. Although majority of CDDs 
are males, the mean implementation fidelity score for males and females are 55.32 and 55.64 
respectively. Only 12% of CDDs have formal training in a health-related field however their 
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mean implementation fidelity score is 65.56 as oppose to 53.93 for those who do not have any 
background health training. In rural areas, implementation fidelity score is 56.36, while in urban 
areas the score is 54.43. The descriptive statistics for other key determinants are presented in 
Table 3.4.  
Table 3.4: Description of other determinants and background characteristics affecting 
implementation fidelity of mass drug administration in Kano State, Nigeria  
Variables  
Community Directed 
Distributors (348)  Percentage IF Mean (SD) 
Median 
(IQR)  
Overall implementation fidelity 348 100 55.39(8.10) 56(49 - 60) 
OTHER DETERMINANTS 
    Knowledge of NTD 
    Inadequate 216 62.07 53.66(7.66) 56(47 - 59) 
Adequate  132 37.93 58.22(8.04)  58(52 - 64) 
Incentive  
    No  286 82.18 55.59(6.80) 56(50 - 60) 
Yes 62 17.82 54.47(12.51) 49(43 - 67) 
Selection of CDD 
    By community members 290 83.33 53.38(6.91) 55(48 - 59) 
By local government staff 20 5.75 65.65(6.35) 67(61 - 72) 
Volunteered 38 10.92 65.34(5.62) 67(63 – 70) 
BACKGROUND CHARACTERISTICS 
    Age group  
    <25 91 26.15 54.96(8.23) 55(48 - 60) 
25 - 29  106 30.46 56.58(8.53) 58(50 - 62) 
30 - 34 60 17.24 55.62(7.12) 57(51 - 60) 
35 and above 91 26.15 54.29(8.01) 56(48 - 59) 
Sex 
    Male 270 77.59 55.32(8.42) 57(48 - 61) 
Female 78 22.41 55.64(6.93) 55(51- 60) 
Marital status 
    Never married  162 46.55 54.48(7.32) 55(48 - 60) 
Ever married  186 53.45 56.19(8.67) 58(49 - 61) 
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Variables  
Community Directed 
Distributors (348)  Percentage IF Mean (SD) 
Median 
(IQR)  
Overall implementation fidelity 348 100 55.39(8.10) 56(49 - 60) 
 
Occupation  
Unemployed 30 8.62 54.80(4.94) 55(52 - 58) 
Student 144 41.38 54.97(7.27) 56(46 - 60) 
Health work 21 6.03 65.43(5.99) 67(62 - 69)  
Teaching 27 7.76 56.67(10.56) 59(49 - 67) 
Trading 46 13.22 56.54(8.84) 58(47 - 63) 
Farming 80 22.99 52.64(7.58) 54(46 - 59) 
Highest level of education  
    Primary education and 
below  32 9.20 55.50(5.59) 57(54 - 59) 
Secondary education  224 64.37 54.52(8.19) 55(47 - 60) 
Tertiary education  92 26.44 57.47(8.31) 58(53 - 62) 
Stable income  
    No  122 35.06 54.38(6.63) 55(49 - 60) 
Yes  226 64.94 55.94(8.76) 57(48 - 61) 
Formal training in a health-related 
field  
    No  305 87.64 53.96(7.22) 55(48 - 59) 
Yes  43 12.36 65.56(6.71) 68(62 - 70) 
Participation in other public health 
activities  
    No  65 18.68 59.91(5.10) 59(58 - 61) 
Yes  283 81.32 54.35(8.31) 55(48 - 60) 
Location characteristics  
    Rural  174 50 56.36(9.86) 58(47 - 63) 
Urban  174 50 54.43(5.72) 55(50 - 59) 
SD = Standard Deviation, IQR = Inter Quartile Range, NTD = Neglected Tropical Diseases and CDD = Community 
Directed Distributors  
 
 
 
 
 42 
 
3.3  FACTORS ASSOCIATED WITH IMPLEMENTATION FIDELITY 
SCORE  
 
Model 1 (Only the four key determinants are modelled) 
In the unadjusted analysis (as shown in the second column of Table 3.4), only quality of delivery 
score is significantly associated with implementation fidelity. For every unit increase in quality 
of delivery score, implementation fidelity score increased by 1.32 (95% CI: 0.40 – 2.25). This is 
similar to the result of the sensitivity analysis using an ordinal logistic regression as shown on 
Table B.14.   
In the multivariable model quality of delivery score and facilitation strategies score, are 
significant at p < 0.05 (as shown in the third column of Table 3.4). The adjusted coefficient of 
quality of delivery score is positive as in the unadjusted model while the coefficient for 
facilitation strategy score is negative indicating that for every unit increase in facilitation 
strategy, implementation fidelity score decreases by 1.40(95%CI: -2.58 - -0.23). The survey 
correlation matrix of the 4 explanatory variables is presented in Table B.12 (Appendix B).  
Model 2 (all determinants modelled including the four key determinants) 
In the unadjusted analysis (as shown in the fourth column of Table 3.4), six determinants; quality 
of delivery score, knowledge of NTD, selection of CDD, occupation of CDD, formal training in 
health-related field, and participation in other public health activities, are significantly associated 
with implementation fidelity. In the multivariable model (as shown in the fifth column of Table 
3.4), 7 predictors; intervention complexity, facilitation strategy, participant responsiveness, 
knowledge of NTD, selection of CDD, formal training in health-related field and participation in 
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other public health activities are significantly associated with implementation fidelity. The 
adjusted coefficients for all predictors in the model are presented in Table 3.5.  
Table 3.5: Unadjusted and adjusted coefficients of factors affecting implementation fidelity 
of mass drug administration for neglected tropical diseases control in Kano State, Nigeria 
 
MODEL 1 MODEL 2 
Variables  Unadjusted Coef. Adjusted Coef. Unadjusted Coef. Adjusted Coef. 
 
Coefficient(95%CI) Coefficient(95%CI) Coefficient(95%CI) Coefficient(95%CI) 
KEY DETERMINANTS 
    Quality of delivery 1.32(0.40 - 2.25) * 1.54(0.72 - 2.36) * 1.32(0.40 - 2.25) * 0.47(-0.08 - 1.03) 
Intervention complexity 0.26( -0.43 - 0.95) -0.23 (-0.66 - 0.21) 0.26( -0.43 - 0.95) -0.62(-0.93 - -0.30) * 
Facilitation strategies  0.45(-1.34 - 2.24) -1.40(-2.58-  -0.23) * 0.45(-1.34 - 2.24) -1.68(-3.05 - -0.32) * 
Participants 
responsiveness 2.07(-1.17 - 5.31) 2.33( -0.20 - 4.85) 2.07(-1.17 - 5.31) 2.99(1.58 - 4.39) * 
      
OTHER DETERMINANTS  
    Knowledge of NTD 
  
1.04(0.04 - 2.04) * 0.75(0.36 - 1.13) * 
Incentive  
    No  
  
REF 
 Yes 
  
-1.12(-10.91 - 8.66) 
 Selection of CDD 
    By community members 
  
REF 
 By local government 
staff 
  
12.27(8.68 - 15.87) ** 7.48(2.85 - 12.11) * 
Volunteered 
  
11.96(8.46 - 15.47) ** 8.38(4.59 - 12.16) ** 
     BACKGROUND 
CHARACTERISTICS 
    Age group  
    <25 
  
REF 
 25 - 29  
  
1.63(-1.16 - 4.42) 
 30 - 34 
  
0.66(-2.85 - 4.18) 
 >35 
  
-0.67(-4.37 - 3.029) 
 Sex 
    Male 
    Female 
  
0.32(-2.85 - 3.49) 
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MODEL 1 MODEL 2 
Variables  Unadjusted Coef. Adjusted Coef. Unadjusted Coef. Adjusted Coef. 
 
Coefficient(95%CI) Coefficient(95%CI) Coefficient(95%CI) Coefficient(95%CI) 
Marital status 
    Never married  
  
REF 
 Ever married  
  
1.71(-1.71 - 5.13) 
  
 
Occupation  
    Non-health work 
  
REF 
 Health work 
  
10.68(7.15 - 14.22) ** -1.64(-5.52 - 2.23) 
Highest level of 
education  
    
Primary education and 
below 
  
REF 
 Secondary education  
  
-0.98(-3.95 - 1.99) 
 Tertiary education  
  
1.97(-1.61 - 5.54) 
 Stable income  
    No  
  
REF 
 Yes  
  
1.56(-2.06 - 5.18) 
  
Formal training in a 
health-related field  
    No  
  
REF 
 Yes  
  
11.60(8.51 - 14.70) ** 7.34(2.61 - 12.07) * 
Participation in other 
public health activities  
    No  
  
REF 
 Yes  
  
-5.55(-8.94 -  -2.17) * -6.16(-9.49 - -2.83) * 
Location characteristics  
    Rural  
  
REF 
 Urban  
  
-1.93(-8.25 - 4.39) 2.16(-2.51 - 6.82) 
     
*significant at P<0.05, **significant at P<0.0001  R2 for model 1 = 0.2354, R2 for model 2 = 0.5330 
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CHAPTER FOUR: DISCUSSION  
 
The present study assessed the level of implementation fidelity among community directed 
distributors in two local governments areas (a rural and an urban setting) in Kano State. In 
addition, the factors affecting implementation fidelity of mass drug administration for 
community based onchocerciasis, lymphatic filariasis, and soil transmitted helminthiasis control 
was assessed. Both assessments were based on the adapted conceptual model for implementation 
fidelity (66).   
Using a 15-item questionnaire based on 5-point Likert scale to measure implementation fidelity, 
it was found that the overall mean implementation fidelity score in both local government areas 
was 55.39 with standard deviation of 8.10. Predictors of implementation fidelity score identified 
in the present study included intervention complexity score, facilitation strategy score, 
participants responsiveness score, knowledge of NTD, selection of CDD, formal training in a 
health-related field and participation in other public health activities.  
In this chapter, the findings presented in the result section is discussed as well as the limitations 
of the research.  
4.1  LIMITATIONS OF THIS STUDY 
 
1. This study relied on self-reported information from community directed distributors. Although 
this was cheaper and easier to implement, it is important to take note of the shortcomings of self-
reported data which include: social desirability bias; where community directed distributors may 
respond to the questions in a way that will appear favorable to the interviewers, difficulty in 
ascertaining data accuracy, selective memory, exaggeration and telescoping.  
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2. No prior research studies on implementation fidelity of mass drug administration for neglected 
tropical diseases were found. This therefore limited the depth at which the findings from this 
research was discussed.  
4.2  MEASURING IMPLEMENTATION FIDELITY  
 
Current perspectives in implementation science advocates the use of adherence as a bottom-line 
measure of implementation fidelity because how an intervention adheres to frequency, dose, 
content and duration prescribed in a manual determines it (66). This current study contributes to 
the understanding of this concept. Measuring adherence to the WHO preventive chemotherapy 
manual in this study gave a clear insight into whether the implementation process of mass drug 
administration in the 2 local governments reflected what was prescribed.  
The overall implementation fidelity score in this study was found to be moderate. This average 
score is about 70% of the maximum obtainable score which implies that some prescribed 
components of the manual are not been implemented as indicated.  
Poor performance in adherence to content (one of the fidelity constructs) contributed to a 
significant lowering of the score. In particular, the extent to which community directed 
distributors adhered to drug dosages and eligibility criteria specified in the WHO was suboptimal 
(24). It was found that many CDDs did not administer 400 mg of albendazole to children above 2 
years while some administered the medications to infants. This is in contrast with the WHO 
recommend dose of 400mg of albendazole for all preschool aged children (above 2 years) and 
adults as far as the community meet the threshold for implementing mass drug administration 
using preventive chemotherapy (24). In addition, the guideline only recommend treatment for 
children above 12 months, as those aged 12 - 23 months are treated with 200 mg of albendazole 
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(24).  Estimating dose of ivermectin based on the height of an individual is preferred over 
observation of physical appearance without any measurement (88). It is the method 
recommended by the WHO, and is widely practiced in both local governments (24, 89). 
However, some administered ivermectin to children less than 90 centimeters in height which is 
in contrast to what had been specified in the manual (24). This scenario may be attributed to the 
demand to treat household members by caregivers and other community members during mass 
drug administration exercises. In this study, there were a high proportion of CDD who did not 
adhere to the eligibility criteria and this has implications. To ensure safe and event-free 
implementation of mass drug administration, the WHO in its manual for preventive 
chemotherapy recommended that seriously ill people, those who have suffered a previous 
adverse reaction, pregnant and lactating women (in case of treatment with ivermectin) should be 
excluded (24). Also, it recommended that scored tablets should be broken into smaller pieces 
before administrating to children to prevent asphyxiation (90). Despite these clear 
recommendations, many CDDs interviewed reported administering medications to people who 
have previously suffered an adverse reaction, or those that were severely ill during the exercise, 
and even to pregnant or lactating women. Even though the drugs used in mass drug 
administration have very good safety records, severe reactions have been reported in some 
people thus necessitating attention during mass treatment (91, 92).  Other aspects of content like 
drug delivery practices is optimal among CDDs. In this study, nearly all CDD calculated the 
dose required for each round of mass drug administration with provision for loss as 
recommended by WHO.  
Constructs like coverage, frequency and duration were consistently high among all community 
directed distributors.  
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4.3  FACTORS ASSOCIATED WITH IMPLEMENTATION FIDELITY  
 
This study found seven predictors of implementation fidelity and they include, intervention 
complexity, facilitation strategy, participant responsiveness, knowledge of NTD, selection of 
CDD, formal training in a health-related field and participation in other public health activities. 
The proportion of variability of implementation fidelity score predicted by these factors is 
significant (about 53%). Surprisingly, provision of incentives didn’t predict implementation 
fidelity of MDA in Nassarawa and Gezawa local government areas.  
Lack of provision of monetary incentives have been associated with higher CDD attrition in 
previous studies, and this is expectedly so because monetary incentives have been found to be a 
strong extrinsic motivator (45, 93, 94). In fact, when individuals are provided incentives 
performance is seen to be highest(93). However, this does not seem to influence implementation 
fidelity in this study. The fact that incentives didn’t predict implementation fidelity suggests that 
other forms of motivation especially intrinsic motivation might play a role (95).   
The identified predictors are grouped into three as follows: 
4.2.1  Key determinants  
 
Participants responsiveness: This predictor was found to have a strong positive association 
with implementation fidelity score of mass drug administration. As expected, when community 
members view an intervention as relevant, they’re more likely to accept it. This high 
acceptability of the intervention results in high coverage which invariably improves 
implementation fidelity (66).  This finding is consistent with previous evidence from a 
community based study in Tanzania which showed that positive sentiments about usefulness of 
the drugs used for lymphatic filariasis control improves coverage (54).     
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Intervention complexity: This study found that as the complexity of mass drug administration 
increases, the implementation fidelity score decreases. Intervention complexity was based on the 
ease, comprehensiveness and description of mass drug administration process in the manual. The 
finding therefore imply that these properties influences how community directed distributors 
adhere to all the prescribed components of the manual. In other implementation science 
literature, it has already been established that complex interventions are more prone to 
modification during implementation thus resulting in poor fidelity (96-98).  
Facilitation strategies: Before implementation of interventions like mass drug administration, 
support strategies like training of community directed distributors and provision of job aids like 
manuals are instituted to ensure that frontline providers implement the intervention uniformly 
and as prescribed (49, 68). However, this study found a negative relationship between facilitation 
strategy and implementation fidelity score even though majority of CDD received training and 
intervention manuals. This finding contrasts a common assertion that support strategies optimize 
implementation fidelity (98). However, it is important to bear in mind that no empirical 
implementation study are yet to demonstrated that support strategies is positively related to 
implementation fidelity (99).  
4.2.2 Other determinants  
 
Knowledge of NTD: The presented study showed that knowledge of neglected tropical diseases 
has a strong moderating effect on implementation fidelity. This is in agreement with a previous 
study (31). Knowledge determines self-efficacy and self-proficiency which are important 
individual level characteristics required for attaining high level of implementation fidelity (31).  
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Selection of CDD: Within the principle of community directed treatment intervention (CDTI), 
which is currently the mainstay strategy employed by NTD control programs, community 
members are responsible for organizing and conducting mass drug administration (100, 101).  
This include selection of community directed distributors (CDDs) that implement the 
intervention in the field (100). Interestingly, this study found that community directed 
distributors (CDDs) selected by local government staffs and those who volunteered to conducted 
mass drug administration implement with higher implementation fidelity compared to those 
selected by community members. Possible explanations might be that those selected by local 
government officials or those that volunteered have previous experience with MDA or other 
public health programs, are more motivated or have participated in additional trainings.  The 
advantage of this is regardless of selection method, all CDDs are residents of their communities 
as such the core principle of CDTI is kept for program sustainability.  
4.2.3  Background characteristics  
 
Formal training in health-related field:  It was found that CDDs with formal training in a 
health-related field had higher implementation fidelity score. This is expected as training 
improve skill proficiency.  
Participation in other public health activities:  In this study, participation in other public 
health activities is associated with a decrease in implementation fidelity score of mass drug 
administration. Although this is inconsistent with a previous study which found that CDD 
participation in other health and development activities didn’t affect the coverage of ivermectin 
distribution, it is important to note that coverage is only one of the four constructs of 
implementation fidelity (66, 102).  
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CHAPTER FIVE:  CONCLUSION AND 
RECOMMENDATION 
 
5.1  CONCLUSION 
 
Although implementation fidelity is not a new concept, it is seldom measured by program 
managers and designers of public health programs like mass drug administration. It is now well 
established that implementing with quality is a prerequisite for achieving set program objectives. 
However, without fidelity assessment, the quality with which mass drug administration is 
conducted cannot be ascertained. Therefore, the current study attempted to measure 
implementation fidelity and identify factors that affect it.  
Objective one: This study demonstrated the feasibility of measuring implementation fidelity of 
mass drug administration programs using an easy and time efficient methodology. This has 
policy application both at state and national level as it could serve as an advocacy tool to solicit 
for inclusion of fidelity assessment in the monitor and evaluation. If the revised national NTD 
masterplan features fidelity assessment, the NTD program at all level will be better positioned to 
not only monitor program outcome but also the implementation process. Moreover, the method 
used in this research is scalable because it can easily be modified to suit different communities.  
Objective two and three: Several factors affecting implementation fidelity were identified in 
this research. But of interest are intervention complexity and participants responsiveness, as they 
could be the target of future implementation strategies. Quality improvement can be used to 
reduce the complexity of the intervention or increase community engagement during mass drug 
administration exercises.  
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In this current study, the relationship between facilitation strategies and implementation fidelity 
was reversed which is not in agreement with the current literature. Going forward, there will be a 
need to conduct more research to ascertain this relationship.  
Lastly, from implementation research perspective, it is important to study the process of 
implementation to ensure that programs are implemented as prescribed in the original design. 
This must be established before an intervention can be said to have led to a program outcome. 
Therefore, this current research makes important contribution to the field.  
5.2  RECOMMENDATIONS 
 
Based on findings from this study, the following recommendations are suggested:  
1. There is a need for more capacity building interventions like trainings on the core 
component of the WHO manual for helminthiasis control especially drug dosage and 
eligibility criteria. Lack of adherence to what was specified in these areas accounted for 
most of the reduction in implementation fidelity score observed in this research.  
2. There is a need to strengthen monitoring and supervision system during mass drug 
administration exercises as gaps were identified in the quality of delivery of the 
intervention.  
3. National and state NTD programs should consider routine fidelity assessment as part of 
monitoring and evaluation data as implementation fidelity data can provide valuable 
information about how CDDs are conducting mass drug administration in the field, as 
well as, important contextual factors that affect fidelity across different settings. These 
implementation data can be used to improve policy, microplanning, and even tailor 
supportive supervision during mass drug administration exercise.   
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4. There is a need for more research on implementation fidelity of mass drug administration 
to generate a strong body of evidence on the dimensions of fidelity relevant to NTD 
control efforts in communities as well as establish factors that affects it.  
5. Lastly, further research is required to investigate the relationship between implementation 
fidelity and facilitation strategies for neglected tropical diseases control programs.  
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APPENDIX B: ADDITIONAL TABLES AND FIGURES  
 
Table B.1: Characteristics of 15-item questionnaire used to assess implementation fidelity  
Items 1 2 3 4 5 
 
N % N % N % N % N % 
Ivermectin and Albendazole were the drugs used in 
combination during the last community based mass 
drug administration.  0 0 
21
0 
60.3
4 3 0.86 21 6.03 
11
4 
32.7
6 
The doses of drugs required for the round of mass drug 
administration in my community is usually calculated 
with provision for loss and wastage of medicines during 
exercise.   0 0 1 0.29 3 0.86 
18
0 
51.7
2 
16
4 
47.1
3 
All members of the community including preschool 
aged children are given similar doses of ivermectin and 
albendazole during mass drug administration exercise.  
8
8 25.29 
17
5 
50.2
9 9 2.59 42 
12.0
7 34 9.77 
Ivermectin and albendazole cannot be administered to 
infants during mass drug administration exercise. 
5
5 15.8 25 7.18 
1
0 2.87 
15
1 
43.3
9 
10
7 
30.7
5 
The dose of Albendazole administered to children 
above 2 years and adults during the mass drug 
administration exercise is 400 milligrams.  
2
5 7.18 
15
1 
43.3
9 
1
6 4.6 93 
26.7
2 63 18.1 
The dosage of ivermectin depends on the height of the 
individual. 0 0 0 0 2 0.57 
16
2 
46.5
5 
18
4 
52.8
7 
Before administering Ivermectin, height must be 
measured using an IVM tablet-pole. 1 0.29 0 0 6 1.72 
16
5 
47.4
1 
17
6 
50.5
7 
Children less than 90 centimeters in height are 
ineligible for mass drug administration with Ivermectin 
and Albendazole. 
7
1 20.4 55 15.8 
1
4 4.02 
14
7 
42.2
4 61 
17.5
3 
Pregnant and lactating women within one week after 
delivery are ineligible for mass drug administration 
with ivermectin and albendazole.  
9
5 27.3 50 
14.3
7 2 0.57 89 
25.5
7 
11
2 
32.1
8 
People who have previously suffered serious adverse 
reaction to the drugs are excluded during mass drug 
administration.  
8
7 25 53 
15.2
3 
2
4 6.9 
10
5 
30.1
7 79 22.7 
Severely ill individuals are excluded from large scale 
mass drug administration exercise for helminthic 
NTDS. 
9
2 26.44 46 
13.2
2 
2
7 7.76 92 
26.4
4 91 
26.1
5 
When drugs are given to younger children, scored 
tablets are broken into smaller pieces and crushed 
before administration.  
4
9 14.08 53 
15.2
3 
5
5 15.8 
14
0 
40.2
3 51 
14.6
6 
Every eligible member of the community was given 
Albendazole and Ivermectin during the mass drug 
administration exercise. 0 0 1 0.29 1 0.29 89 
25.5
7 
25
7 
73.8
5 
Mass drug administration with combined ivermectin 
and albendazole is conducted yearly. 0 0 0 0 
1
3 3.74 
11
0 
31.6
1 
22
5 
64.6
6 
I conducted mass drug administration exercise in my 
community within the specified number of days. 4 1.15 7 2.01 8 2.3 
10
3 29.6 
22
6 
64.9
4 
 
 
 62 
 
Table B.2: Cronbach alpha of each of the 15-items for assessing implementation fidelity 
Item Observation Sign 
Item-test 
correlation 
Item-rest 
correlation 
Average 
interitem 
covariance alpha 
Ivermectin and Albendazole were the drugs used in 
combination during the last community based mass 
drug administration.  348 - 0.51 0.37 0.27 0.7798 
The doses of drugs required for the round of mass 
drug administration in my community is usually 
calculated with provision for loss and wastage of 
medicines during exercise.   348 - 0.24 0.18 0.3 0.7895 
All members of the community including preschool 
aged children are given similar doses of ivermectin 
and albendazole during mass drug administration 
exercise.  348 + 0.69 0.6 0.25 0.759 
Ivermectin and albendazole cannot be administered 
to infants during mass drug administration exercise. 348 + 0.43 0.28 0.28 0.7881 
The dose of Albendazole administered to children 
above 2 years and adults during the mass drug 
administration exercise is 400 milligrams.  348 + 0.2 0.05 0.31 0.8069 
The dosage of ivermectin depends on the height of 
the individual. 348 - 0.08 0.02 0.31 0.7948 
Before administering Ivermectin, height must be 
measured using an IVM tablet-pole. 348 - 0.16 0.09 0.31 0.7927 
Children less than 90 centimeters in height are 
ineligible for mass drug administration with 
Ivermectin and Albendazole. 348 + 0.81 0.74 0.22 0.7418 
Pregnant and lactating women within one week 
after delivery are ineligible for mass drug 
administration with ivermectin and albendazole.  348 + 0.83 0.76 0.21 0.7365 
People who have previously suffered serious 
adverse reaction to the drugs are excluded during 
mass drug administration.  348 + 0.85 0.8 0.21 0.7336 
Severely ill individuals are excluded from large 
scale mass drug administration exercise for 
helminthic NTDS. 348 + 0.85 0.78 0.21 0.7345 
When drugs are given to younger children, scored 
tablets are broken into smaller pieces and crushed 
before administration.  348 + 0.62 0.52 0.25 0.7658 
Every eligible member of the community was given 
Albendazole and Ivermectin during the mass drug 
administration exercise. 348 + -0.02 -0.07 0.32 0.7971 
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Item Observation Sign 
Item-test 
correlation 
Item-rest 
correlation 
Average 
interitem 
covariance alpha 
Mass drug administration with combined ivermectin 
and albendazole is conducted yearly. 348 - 0.12 0.05 0.31 0.7941 
I conducted mass drug administration exercise in 
my community within the specified number of days. 348 + 0.12 0.04 0.31 0.7967 
Test scale         0.27 0.7887 
 
 
Table B.3: Bartlett test and KMO Measure of sampling adequacy of the 15-items  
Bartlett test of sphericity   
Chi-square 2512.433 
Degrees of freedom           105 
p-value          < 0.001 
H0: variables are not intercorrelated 
 
Kaiser-Meyer-Olkin Measure of 
Sampling Adequacy   
KMO           0.827 
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Table B.4: Polychoric correlation matrix of 15-items for assessing implementation fidelity 
  
drug 
combinati
on 
dose 
calculati
on 
dose 
similari
ty 
ivermecti
n and 
albendaz
ole 
albendaz
ole dose 
ivermect
in dose 
administ
er 
ivermect
in 
ineligibl
e1 
ineligibl
e2 
ineligibl
e3 
ineligibl
e4 
drug
s 
chil
d 
Covera
ge 
Frequen
cy 
Durati
on 
drug 
combination 1.00 
              
dose calculation 0.65 1.00 
             
dose similarity -0.58 -0.14 1.00 
            ivermectin and 
albendazole -0.18 0.08 0.26 1.00 
           albendazole 
dosage -0.24 0.20 0.33 0.45 1.00 
          ivermectin 
dosage 0.45 0.52 -0.17 0.24 0.16 1.00 
         administer 
ivermectin 0.48 0.43 -0.22 0.18 0.14 0.62 1.00 
        
ineligible1 -0.40 -0.12 0.67 0.23 0.10 0.05 0.00 1.00 
       
ineligible2 -0.25 -0.20 0.58 0.14 -0.06 0.00 -0.11 0.80 1.00 
      
ineligible3 -0.48 -0.28 0.61 0.19 0.02 0.03 -0.08 0.76 0.87 1.00 
     
ineligible4 -0.43 -0.23 0.58 0.18 0.02 0.09 -0.05 0.76 0.89 0.90 1.00 
    
drugs child -0.08 0.17 0.46 0.19 0.17 0.25 0.11 0.58 0.56 0.59 0.64 1.00 
   
coverage 0.65 0.33 -0.22 0.00 -0.04 0.48 0.55 0.03 0.14 0.03 0.03 0.25 1.00 
  
Frequency 0.21 0.24 -0.23 0.08 0.11 0.55 0.44 -0.01 -0.11 -0.11 -0.04 0.13 0.46 1.00 
 
Duration 0.29 0.25 -0.08 0.09 -0.03 0.45 0.43 0.16 0.11 0.08 0.18 0.28 0.49 0.52 1 
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Table B.5: Unrotated Factor Score 
Factor Eigenvalue Difference Proportion  Cumulative 
Factor 1 4.81 1.20 0.40 0.40 
Factor 2 3.61 2.25 0.30 0.70 
Factor 3  1.36 0.51 0.11 0.81 
Factor 4 0.85 0.44 0.07 0.89 
Factor 5 0.41 0.04 0.03 0.92 
Factor 6 0.37 0.13 0.03 0.95 
Factor 7 0.24 0.06 0.02 0.97 
Factor 8 0.18 0.08 0.02 0.99 
Factor 9 0.10 0.03 0.01 0.99 
Factor 10 0.07 0.01 0.01 1.00 
Factor 11 0.06 0.02 0.00 1.01 
Factor 12 0.04 0.04 0.00 1.01 
Factor 13  0.00 0.04 0.00 1.01 
Factor 14 -0.04 0.01 0.00 1.00 
Factor 15                         -0.06    .    0.00 1.00 
Chi2 = 4770.30 p= <0.0001 
 
Figure B.1: Scree plot of eigen values 
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Table B.6: Rotated factors 
Variable Factor 1 Factor 2 Factor 3 Uniqueness 
drug combination -0.6594 0.5423 -0.3353 0.1586 
dose calculation -0.3616 0.5702 0.2428 0.4851 
dose similarity 0.7784 -0.05 0.302 0.3004 
ivermectin and albendazole 0.2265 0.2108 0.4712 0.6822 
albendazole dosage 0.1305 0.1378 0.7605 0.3856 
ivermectin dosage -0.1546 0.7878 0.1604 0.3298 
administer ivermectin -0.2523 0.7048 0.1167 0.4259 
ineligible1 0.833 0.2622 -0.0107 0.2373 
ineligible2 0.8657 0.246 -0.3135 0.0917 
ineligible3 0.9102 0.1848 -0.1502 0.1148 
ineligible4 0.8966 0.2599 -0.1667 0.1007 
drugs child 0.5767 0.4773 0.0272 0.4389 
coverage -0.1755 0.7579 -0.2884 0.3116 
Frequency -0.2072 0.6131 0.1045 0.5703 
Duration -0.0176 0.6311 -0.098 0.5918 
 
Table B.7: Varimax orthogonal rotation of factors 
Factor  Variance Difference Proportion Cummulative 
Factor1 4.57430      0.86142 0.3813 0.3813 
Factor2 3.71289      2.22492 0.3095 0.6908 
Factor3 1.48797            . 0.124 0.8148 
 
Table B.8: Pattern of rotated factor loading matrix and uniqueness variance 
Variable Factor 1 Factor 2 Factor 3 Uniqueness 
drug combination -0.39 0.74 -0.37 0.16 
dose calculation 
 
0.64 
 
0.49 
dose similarity 0.65 -0.31 0.42 0.30 
ivermectin and albendazole 
  
0.52 0.68 
albendazole dosage 
  
0.78 0.39 
ivermectin dosage 
 
0.78 
 
0.33 
administer ivermectin 
 
0.74 
 
0.43 
ineligible1 0.86 
  
0.24 
ineligible2 0.94 
  
0.09 
ineligible3 0.94 
  
0.11 
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Variable Factor 1 Factor 2 Factor 3 Uniqueness 
ineligible4 0.95 
  
0.10 
drugs child 0.67 
  
0.44 
coverage 
 
0.79 
 
0.31 
Frequency 
 
0.64 
 
0.57 
Duration   0.61   0.59 
Blanks represents absolute loading < 0.3  
Table B.9: Factor rotation matrix 
  Factor 1 Factor 2 Factor 3 
Factor 1 0.9367 -0.3066 0.1689 
Factor 2 0.2887 0.9495 0.1226 
Factor 3 -0.198 -0.0661 0.978 
 
Table B.10: Scoring coefficient of varimax rotated factors using regression method 
Variables Factor 1 Factor 2 Factor 3 
drug combination -0.21 2.20 -2.74 
dose calculation 0.02 -0.40 0.93 
dose similarity 0.03 0.33 -0.21 
ivermectin and 
albendazole -0.02 0.13 0.03 
albendazole dosage -0.05 0.27 0.08 
ivermectin dosage 0.03 -0.19 0.65 
administer ivermectin 0.03 -0.17 0.48 
ineligible1 0.11 0.59 -0.56 
ineligible2 0.44 -1.73 1.73 
ineligible3 0.14 0.96 -1.22 
ineligible4 0.18 1.04 -1.15 
drugs child 0.10 -0.22 0.37 
coverage 0.10 -0.28 0.56 
Frequency -0.02 0.66 -0.52 
Duration 0.04 -0.07 0.14 
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Table B.11: Characteristics of items of key determinants of implementation fidelity  
 
1 2 3 4 5 
Variables  N % N % N % N % N % 
Quality of Delivery 
          There was good supportive supervision 
from local and state government officials 
during the mass drug administration 
exercise. 63 18.1 241 69.25 1 0.29 16 4.6 27 7.76 
The drugs (ivermectin and albendazole) 
were available to me for distribution to 
community members on the scheduled 
day. 2 0.57 2 0.57 1 0.29 137 39.37 206 59.2 
Adequate number of IVM tablet-pole were 
available for use during the mass drug 
administration exercise.  4 1.15 24 6.9 20 5.75 168 48.28 132 37.93 
Adequate number of weighing scales were 
available for use during the mass drug 
administration exercise.  223 64.08 57 16.38 5 1.44 31 8.91 32 9.2 
The community was adequately sensitized 
through community mobilization activities 
before the commencement of mass drug 
administration exercise 11 3.16 30 8.62 13 3.74 155 44.54 139 39.94 
Intervention complexity 
          How would you rate the ease of the 
current process of conducting mass drug 
administration? 100 28.74 57 16.38 10 2.87 92 26.44 89 25.57 
How would you rate the description of 
responsibility in the manual provided? 21 6.03 41 11.78 28 8.05 140 40.23 118 33.91 
How would you rate the information 
provided in the manual?  14 4.02 5 1.44 17 4.89 192 55.17 120 34.48 
Facilitation strategies  
          I was properly training on community 
based mass drug administration with 
ivermectin and albendazole 0 0 0 0 3 0.86 185 53.16 160 45.98 
I received a training manual and other job 
aids on mass drug administration  1 0.29 2 0.57 12 3.45 185 53.16 148 42.53 
Participants responsiveness  
          Community members were cooperative 
during the mass drug administration 
exercise  0 0 0 0 6 1.72 119 34.2 223 64.08 
 
 
 
 69 
 
Table B.12: Survey correlation matric of predictors of implementation fidelity 
Variables 
QD 
score 
IC 
score 
FS 
score 
PR 
score  Knowledge  Selection  Occupation  Training  
Participate 
PH  
Location 
xtics 
QD score 1 
         IC score 0.42 1 
        FS score 0.35 0.31 1 
       PR score  0.15 0.12 0.5 1 
      Knowledge  0.47 0.42 0.44 0.23 1 
     Selection  0.47 0.41 0.1 -0.09 0.28 1 
    
Occupation  0.37 0.24 0.09 
-
0.002 0.18 0.43 1 
   Training  0.43 0.35 0.13 0.003 0.22 0.61 0.49 1 
  
Participate 
PH  0.12 0.14 0.09 0.02 0.21 -0.17 -0.09 0.09 1 
 Location 
xtics 0.11 -0.03 0.28 0.25 0.39 -0.38 -0.25 -0.34 0.41 1 
 
Table B.13: Survey correlation matrix of key determinants of implementation fidelity  
Variables QD score IC score FS score PR score 
QD score 1 
   
IC score 0.42 1 
  
FS score 0.35 0.31 1 
 
PR score 0.15 0.12 0.5 1 
 
Table B.14: Unadjusted odds ratio of key factors affecting implementation fidelity of mass 
drug administration for neglected tropical diseases control in Kano State, Nigeria 
Variables  
Unadjusted OR 
(95% CI) p-Value 
KEY DETERMINANTS 
  Quality of delivery 1.29(1.02 - 1.64) 0.039 
Intervention complexity 1.02(0.89 - 1.19) 0.719 
Facilitation strategies  0.94(0.62 - 1.42) 0.739 
Participants responsiveness 1.40(0.64 - 3.06) 0.367 
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APPENDIX C: PUBMED SEARCH STRATEGY 
 
 Query 
#1  "mass drug administration" OR “preventive chemotherapy” [MeSH Terms] 
#2 “community based” OR “community” OR “rural” 
#3 #1 AND #2  
#4 “lymphatic filariasis” OR “onchocerciasis” OR “soil transmitted helminthiasis” 
OR “schistosomiasis” OR “buruli ulcer” OR “chagas disease” OR “dengue” OR 
“chikungunya” OR “dracunculiasis” OR “echinococcosis” OR “foodborne 
trematodiases” OR “human African trypanosomiasis” OR “leishmaniasis” OR 
“leprosy” OR “rabies” OR “trachoma” OR “yaws” OR “taeniasis” OR 
“cysticercosis” OR “guinea worm disease” OR “sleeping sickness” OR “hansen’s 
disease” OR “river blindness” OR “endemic treponematoses” OR “yaws” OR 
“taeniasis” 
#5 “neglected tropical diseases” OR ''neglected diseases" OR "tropical diseases" OR 
“neglected tropical disease” OR ''neglected disease" OR "tropical disease" [MeSH 
Terms] 
#6 #4 OR #5  
#7 #3 AND #6 
#8 (Afghanistan OR Islamic Republic of Afghanistan OR Bangladesh OR People's 
Republic of Bangladesh OR Benin OR Dahomey OR Republic of Benin OR 
Burkina Faso OR Burkina OR Republic of Upper Volta OR Burundi OR Republic 
of Burundi OR Cambodia OR Kingdom of Cambodia OR Central African 
Republic OR Chad OR Republic of Chad OR Comoros OR Union of the Comoros 
OR Democratic Republic of the Congo OR DR Congo OR Congo-Kinshasa OR 
DRC OR Zaire OR Eritrea OR State of Eritrea OR Ethiopia OR Federal 
Democratic Republic of Ethiopia OR The Gambia OR Republic of the Gambia OR 
Guinea OR Republic of Guinea OR Guinea-Conakry OR Guinea-Bissau OR 
Republic of Guinea-Bissau OR Haiti OR Republic of Haiti OR Kenya OR 
Republic of Kenya OR North Korea OR Democratic People's Republic of Korea 
OR Kyrgyz Republic OR Kyrgyzstan OR Liberia OR Republic of Liberia OR 
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Madagascar OR Republic of Madagascar OR Malawi OR Republic of Malawi OR 
The Warm Heart of Africa OR Mali OR Republic of Mali OR Mozambique OR 
Republic of Mozambique OR Myanmar OR Burma OR Republic of the Union of 
Myanmar OR Nepal OR Democratic Republic of Nepal OR Niger OR Republic of 
Niger OR Rwanda OR Republic of Rwanda OR Sierra Leone OR Republic of 
Sierra Leone OR Somalia OR Federal Republic of Somalia OR South Sudan OR 
Republic of South Sudan OR Tajikistan OR Republic of Tajikistan OR Tanzania 
OR United Republic of Tanzania OR Republic of Tanganyika and Zanzibar OR 
Togo OR Togolese Republic OR Uganda OR Republic of Uganda OR Zimbabwe 
OR Republic of Zimbabwe OR Rhodesia) 
#9 (Armenia OR armenia OR Bhutan OR Kingdom of Bhutan OR Bolivia OR 
Plurinational State of Bolivia OR Cameroon OR Republic of Cameroon OR 
Republic of Cameroun OR Cape Verde OR Republic of Cape Verde OR Cote 
D'ivoire OR Ivory Coast OR Republic of Cote D'ivoire OR Djibouti OR Republic 
of Djibouti OR Arab Republic of Egypt OR Egypt OR El Salvador OR Georgia 
OR Ghana OR Republic of Ghana OR Guatemala OR Republic of Guatemala OR 
Guyana OR Co-operative Republic of Guyana OR Honduras OR Republic of 
Honduras OR Spanish Honduras OR Republic of Indonesia OR Indonesia OR 
India OR Republic of India OR Kiribati OR Republic of Kiribati OR Kosovo OR 
Kosovo and Metohija OR Laos OR Lao Lao People's Democratic Republic OR 
Lesotho OR Kingdom of Lesotho OR Mauritania OR Islamic Republic of 
Mauritania OR Micronesia, Fed. Sts. OR Federated States of Micronesia OR FSM 
OR Moldova OR Republic of Moldova OR Mongolia OR Morocco OR Kingdom 
of Morocco OR Nicaragua OR Republic of Nicaragua OR Nigeria OR Federal 
Republic of Nigeria OR Pakistan OR Islamic Republic of Pakistan OR Papua New 
Guinea OR Independent State of Papua New Guinea OR Paraguay OR Republic of 
Paraguay OR Philippines OR Republic of the Philippines OR Samoa OR 
Independent State of Samoa OR Sao Tome and Principe OR Democratic Republic 
of Sao Tome and Principe OR Senegal OR Republic of Senegal OR Solomon 
Islands OR Sri Lanka OR Democratic Socialist Republic of Sri Lanka OR Sudan 
OR Republic of the Sudan OR North Sudan OR Swaziland OR Kingdom of 
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Swaziland OR Ngwane OR Yuwatini OR Syrian Arab Republic OR Syria OR East 
Timor OR Timor-Leste OR Democratic Republic of Timor-Leste OR Ukraine OR 
Uzbekistan OR Republic of Uzbekistan OR Vanuatu OR Republic of Vanuatu OR 
Vietnam OR the Socialist Republic of Vietnam OR West Bank and Gaza OR 
Yemen OR Yemeni Republic OR Zambia OR Republic of Zambia.) 
#10 (Angola OR Republic of Angola OR Albania OR Republic of Albania OR Algeria 
OR The People's Democratic Republic of Algeria OR American Samoa OR 
Argentina OR Azerbaijan OR Belarus OR Belize OR Bosnia and Herzegovina OR 
Bosnia-Herzegovina OR Bosnia OR Botswana OR Brazil OR Federative Republic 
of Brazil OR Bulgaria OR China OR People's Republic of China OR Colombia 
OR Costa Rica OR Fiji OR Gabon OR Gabonese Republic OR Grenada OR 
Hungary OR Islamic Republic of Iran OR Persia OR Iran OR Iraq OR Jamaica OR 
Jordan OR Hashemite Kingdom of Jordan OR Kazakhstan OR Lebanon OR 
Lebanese Republic OR Libya OR State of Libya OR Macedonia OR Republic of 
Macedonia OR Malaysia OR Maldives OR Republic of the Maldives OR 
Maldives Islands OR Marshall Islands OR Republic of the Marshall Islands OR 
Palau OR Republic of Palau OR Panama OR Republic of Panama OR Peru OR 
Romania OR Serbia, OR the Republic of Serbia OR Seychelles OR the Republic 
of Seychelles OR South Africa OR Saint Lucia OR Saint Vincent and the 
Grenadines OR Suriname OR Thailand OR Kingdom of Thailand OR Tonga OR 
Kingdom of Tonga OR Tunisia OR Turkey OR Turkmenistan OR Turkmenia OR 
Cuba OR Dominica OR Commonwealth of Dominica OR The Dominican 
Republic OR Ecuador OR Mauritius OR Mexico OR United Mexican States OR 
Montenegro OR Namibia OR Tuvalu OR Ellice Islands OR Venezuela OR the 
Bolivarian Republic of Venezuela) 
#11 (Low-income country OR lower-income country OR third-world country OR 
middle-income country) 
#12 developing countries [MeSH Terms] 
#13 #8 OR #9 OR #10 OR #11 OR #12 
#10 #7 AND #13 
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APPENDIX D: QUESTIONNAIRE  
 
QUESTIONNAIRE 
QUESTIONNAIRE ID: …………………………… 
NAME OF LOCAL GOVERNMENT: ____ NAME OF WARD (CLUSTER): ______ 
CLUSTER NUMBER: _________   CHARACTERISTICS OF LOCATION: RURAL/URBAN 
SECTION A: BACKGROUND DEMOGRAPHICS AND SOCIOECONOMIC DATA 
1. Age  ______________ 
2. Sex   1] Male  2] Female 
3. Marital status 1] Never married  2] Married 3] Separated 4] Divorced  5] 
Widowed 
4. Occupation  1] No occupation 2] Student 3] Health worker 4] Teacher  5] 
Petty Trader  6] Other (specify) ------------------- 
5. Do you currently have a stable source of income? 1] Yes  2] No 
6. What is your monthly income? __________________________ 
7. What is your highest level of educational? 1] No formal education   2] Primary 
education 3] Secondary education 4] Tertiary education 
8. Do you have any formal training in a health-related field? 1] Yes 2] No 
9. If yes, which health related field have you received training in?  1] Community 
Health   3] Environmental Health  4] Nursing 5] Medicine 6] 
Others (specify) ---------------------------- 
10. Do you participate in other public health activities apart from mass drug administration 
exercise in your community?  1] Yes  2] No 
11. If yes, which other public health activity have you participated in, in the last 12 months? 
1] Immunization campaigns 2] Nutritional campaigns  3] Community Tuberculosis 
Campaign 4] Others (Specify) --------------------------------- 
SECTION B: LEVEL OF KNOWLEDGE OF COMMUNITY DRUG DISTRIBUTORS 
1. The full meaning of NTD is Neglected Tropical Disease.  1) Strongly disagree 2) 
Disagree  3) Neutral   4) Agree  5) Strongly agree 
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2. NTDs are considered diseases of public health importance.  1) Strongly disagree 2) 
Disagree  3) Neutral   4) Agree  5) Strongly agree 
3.  Mass drug administration for control of schistosomiasis is school based in Kano State. 1) 
Strongly disagree 2) Disagree  3) Neutral   4) Agree  5) 
Strongly agree  
4. Mass drug administration for control of lymphatic filariasis, soil transmitted 
helminthiasis and onchocerciasis is community based in Kano State. 1) Strongly disagree
 2) Disagree  3) Neutral   4) Agree  5) Strongly agree 
SECTION C: IMPLEMENTATION OF MASS DRUG ADMINISTRATION BY 
COMMUNITY DRUG DISTRIBUTORS 
CONTENT 
1. Ivermectin and Albendazole were the drugs used in combination during the last 
community based mass drug administration.      
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
2. The doses of drugs required for the round of mass drug administration in my community 
is usually calculated with provision for loss and wastage of medicines during exercise.   
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree  
3. All members of the community including preschool aged children were given similar 
doses of albendazole during mass drug administration exercise.      
1) Strongly disagree 2) Disagree  3) Neutral   4) Agree  5) 
Strongly agree 
5. Ivermectin and albendazole can be administered to infants during mass drug 
administration exercise.          
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
6. The dose of Albendazole administered to children above 2 years and adults during the 
mass drug administration exercise is 400 milligrams.     
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 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
7. The dosage of ivermectin depends on the height of the individual.    
  1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
8. Before administering Ivermectin, height must be measured using an IVM tablet-pole. 
  1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree  
9. Children less than 90 centimeters in height are ineligible for mass drug administration 
with Ivermectin and Albendazole.         
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree  
10. Pregnant and lactating women within one week after delivery are ineligible for mass drug 
administration with ivermectin and albendazole.      
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
11. People who have previously suffered serious adverse reaction to the drugs are excluded 
during mass drug administration.        1) 
Strongly disagree 2) Disagree  3) Neutral   4) Agree  5) 
Strongly agree 
12.  Severely ill individuals are excluded from large scale mass drug administration exercise 
for helminthic NTDS.         
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
13. When drugs are given to younger children, scored tablets are broken into smaller pieces 
and crushed before administration.        
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
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COVERAGE 
14. Every eligible member of the community was given Albendazole and Ivermectin during 
the mass drug administration exercise.      
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree  
15. If strongly disagree, please specify reasons why they were not reached. ____________  
FREQUENCY 
16. Mass drug administration with combined ivermectin and albendazole is conducted yearly. 
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
 DURATION 
17. I conducted mass drug administration exercise in my community within the specified 
number of days.          
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
SECTION D: FACTORS AFFECTING IMPLEMENTATION FIDELITY 
QUALITY OF DELIVERY 
1. There was good supportive supervision from local and state government official during 
the mass drug administration exercises.       
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
2. The drugs (Ivermectin and Albendazole) were available to me for distribution to 
community members on the scheduled day.       
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
3. Adequate number of IVM tablet-pole were available for use during the mass drug 
administration exercise.          
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 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
4. Adequate number of weighing scales were available for use during the mass drug 
administration exercise.         
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
5. The community was adequately sensitized through community mobilization activities 
before the commencement of mass drug administration exercise.     
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
INTERVENTION COMPLEXITY 
1. How would you rate the ease of the current process of conducting mass drug 
administration?          
 1] Very complex 2] Somewhat complex  3] Neither 4] Somewhat 
simple  5] Very simple 
2. How would you rate the information provided in the manual?     
 1] Very vague 2] Somewhat vague 3] Neither 4] Detailed 5] Very 
detailed 
3. How would you rate the description of responsibility in the manual provided?   
 1] Very complex 2] Somewhat complex 3] Neither 4] Somewhat simple
 5] Very simple 
FACILITATION STRATEGIES 
4. I was properly trained on community based mass drug administration with Ivermectin 
and Albendazole.          
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
5. I receive a training manual or job aids on mass drug administration.    
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree  
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PARTICIPANT RESPONSIVENESS  
6. Community members were cooperative during the mass drug administration exercise. 
 1) Strongly disagree 2) Disagree  3) Neutral   4) Agree 
 5) Strongly agree 
CDD SELECTION PROCESS 
7. How were you selected to become a community directed distributor in your locality? 1] 
Selected by community members 2] Selected by local government authority 3] 
Volunteered  4] Others (please specify) ________________________ 
AVAILABILITY OF INCENTIVES 
8. Do you receive any incentive for conducting mass drug administration in your 
community?  1) Yes  2) No 
9. If yes, who provided incentives? 1] State Government  2) Local Government 
 3] Community members 
10. I am satisfied with the incentives I received for conducting mass drug administration in 
my community.  1) Strongly disagree  2) Disagree 3) Neutral 4) Agree
 5) Strongly agree 
11. What kind of incentives did you receive while conducting mass drug administration in 
your community?   
12. 1] Monetary incentives 2] Food items  3] Others (please specify) 
__________ 
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APPENDIX E: INFORMATION SHEET 
 
 
PARTICIPANTS’ INFORMATION SHEET 
Good Day 
My name is Abdu Adamu and I am a Masters student in the Division of Epidemiology and 
Biostatistics, School of Public Health at the University of the Witwatersrand, Johannesburg, 
South Africa. I am conducting a study to know how well community-based mass drug 
administration for onchocerciasis, lymphatic filariasis, and soil transmitted helminthiasis is done 
in Kano State. 
The reason why I am conducting this study is because these neglected tropical diseases are a 
major cause of morbidity and with high economic consequences too. Data collected will be 
compiled in a thesis report, and may be shared in publications or presentations.  
As a community directed distributor that have been involved in conducting mass drug 
administration, I would like to invite you to participate in this study because your response is 
important. Before you decide to take part, you need to understand why the research is being 
conducted and what would be required of you. Therefore, take your time to read this information 
sheet carefully. Please ask any question if anything you have read is not clear or would like 
further information.  
The entire survey will take about 30 minutes and it will be conducted in Hausa Language. The 
survey is confidential and anonymous. This is guaranteed by not needing to indicate your name 
on questionnaire. If you decide to take part in this study, be assured that your participation is 
voluntary and you are free to withdraw at any time without giving any reason. There are no risk, 
penalty or loss of benefits whether you participate or not.  
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If you have any concerns or questions regarding any aspect of this study or wish to obtain a copy 
of the results of the survey, please kindly contact me on;  
Name: Abdu Adamu   Tel: (+234)8065459980       
  Email: 815633@students.wits.ac.za and abdu.adamu@gmail.com 
For questions regarding participants’ rights and ethical conduct of research, please contact:  
Hamza Ahmad        
Director Planning Research and Statistics 
Kano State Ministry of Health Research Ethics Committee 
Tel: +23464634233 
 
Peter Cleaton-Jones 
Wits Human Research Ethics Committee (Medical) 
University of the Witwatersrand, Johannesburg 
Email: peter.cleaton-jones1@wits.ac.za  
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APPENDIX F: INFORMED CONSENT FORM 
 
INFORMED CONSENT FORM  
I, ________________________________________ consent and volunteer to participate in a 
research looking at how well community based integrated mass drug administration for 
onchocerciasis, lymphatic filariasis and soil transmitted helminthiasis control in Kano State is 
being done. The study is being conducted by Abdu Adamu; a Master’s student from University 
of the Witwatersrand, Johannesburg, South Africa.  
I confirm that: 
1. I was provided with an information sheet that explained what the study is about I have 
read and understood the information about the study as provided in the information sheet.  
2. I have been given the opportunity to ask questions about the project and my participation.  
3. I understand that I will not be paid for participating in the study.  
4. I understand that I can withdraw at any time without giving reasons and there are will be 
no risks or penalty for withdrawing  
5. It has been clearly explained to me that the research is confidential and anonymous. i.e. 
and what I say will not be linked to me as a person and that the information will only be 
used for this research purpose and not shared with other people that are not part of this 
research team.  
6. It has been clearly explained to me that information from this research may be used in a 
thesis report, publications or presentations.  
7. I understand that mobile tablet devices will be used in the collection of data.  
 
Participant  
_________________________ ____________________       _______________________ 
Name     Signature   Place and date 
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APPENDIX G: FIELD DATA COLLECTORS ‘CONFIDENTIALITY 
AGREEMENT 
 
Field Data Collectors’ Confidentiality Agreement 
This study; assessing implementation fidelity of community based integrated mass drug 
administration for neglected tropical disease control in Kano State, Nigeria, is being undertaken 
by Dr Abdu Adamu, a postgraduate student at Wits School of Public Health, University of the 
Witwatersrand, Johannesburg, South Africa. 
I, __________________________________, agree to: 
1. Keep all the research information shared with me confidential by not discussing or 
sharing the research information in any form or format with anyone other than the 
Principal Investigator; 
2. Keep all research information in any form or format secure while it is in my possession; 
3. Return all research information in any form or format to the Principal Investigator when I 
have completed the research tasks.  
Field Data Collector: 
 ________________________        __________________________   ________________ 
        (print name)                                         (signature)                                   (date)      
Principal Investigator: 
________________________        __________________________   ________________ 
        (print name)                                         (signature)                                   (date)      
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APPENDIX H: ETHICS APPROVAL LETTER FROM KANO STATE 
MINISTRY OF HEALTH 
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APPENDIX I: WITS HUMAN RESEARCH ETHIC COMMITTEE (HREC) 
CLEARANCE CERTIFICATE 
 
 
